[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 159
1. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jerónimo C: Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl); 2006 Nov;84(11):911-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
  • To assess Cyclin D2 promoter methylation status and expression levels in prostate tissues, quantitative methylation-specific PCR and quantitative reverse transcription PCR assays were performed in a large series of prostate carcinomas, high-grade prostatic intraepithelial neoplasias (HGPIN), benign prostate hyperplasias (BPH), normal prostate tissue (NPT) samples, and prostate cancer (PCa) cell lines (before and after demethylating treatment).
  • Methylation levels were significantly higher in PCa compared with HGPIN, NPT, and BPH (P<0.0001), correlating with tumor stage and Gleason score (r=0.29, P=0.0014; and r=0.32, P=0.0005, respectively).
  • Demethylating treatment induced a substantial increase in Cyclin D2 mRNA in LNCaP cells whereas decreased levels were observed in DU-145 and PC-3 cells.
  • Conversely, high Cyclin D2 methylation levels characterize invasive prostatic carcinoma, correlating with clinicopathologic features of tumor aggressiveness.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclins / genetics. DNA Methylation. Gene Expression Regulation, Neoplastic. Prostatic Hyperplasia / genetics. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Line, Tumor. Cell Transformation, Neoplastic / genetics. Cyclin D2. DNA Modification Methylases / antagonists & inhibitors. Enzyme Inhibitors / pharmacology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Promoter Regions, Genetic. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Mol Med (Berl). 2006 Nov;84(11):883-5 [17021907.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):338-45 [16012517.001]
  • [Cites] Mol Cancer. 2004 Dec 01;3:33 [15574200.001]
  • [Cites] Curr Opin Cell Biol. 1999 Dec;11(6):655-62 [10600701.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1747-52 [11717336.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] Annu Rev Med. 1999;50:401-23 [10073286.001]
  • [Cites] J Pathol. 1999 Oct;189(2):194-200 [10547574.001]
  • [Cites] Nucleic Acids Res. 1996 Dec 15;24(24):5064-6 [9016686.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8321-5 [16322291.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):103-15 [15657340.001]
  • [Cites] J Virol. 1995 Feb;69(2):1292-5 [7529333.001]
  • [Cites] EMBO J. 1994 Jul 15;13(14 ):3321-8 [8045261.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3163-72 [9584157.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):660-9; discussion 669 [15474280.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1446-52 [12684418.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):332-9 [10050866.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Oncogene. 1993 Aug;8(8):2127-33 [8336939.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1274-8 [15894685.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4730-4 [14581343.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):470-4 [8945475.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1560-5 [12771922.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):585-94 [10666388.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2782-7 [11289162.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):341-5 [14506731.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):514-9 [11839671.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4010-4 [15217932.001]
  • (PMID = 17016690.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Enzyme Inhibitors; 0 / RNA, Messenger; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


2. Takei H, Goodman JC, Tanaka S, Bhattacharjee MB, Bahrami A, Powell SZ: Pituicytoma incidentally found at autopsy. Pathol Int; 2005 Nov;55(11):745-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pituicytoma is a rare benign neoplasm, occurring in the sellar and suprasellar regions.
  • The tumor was composed primarily of bipolar, occasionally unipolar, cells with syncytial fibrillary cytoplasm, arranged in short curvilinear fascicles and/or storiform patterns.
  • Unusual histological features were seen, which included a few groups of large pleomorphic tumor cells with abundant, glassy, eosinophilic cytoplasm, occasionally associated with multinucleated giant tumor cells, and scattered Herring bodies within the tumor.
  • Immunohistochemically, the tumor showed diffuse strong expression of glial fibrillary acidic protein, S-100 protein, and vimentin.
  • Epithelial membrane antigen immunoreactivity was focally observed, mainly in the large tumor cells.
  • Distinction from other intrasellar tumors (granular cell tumor and pilocytic astrocytoma) is important.
  • Because the immunohistochemical profiles of these tumors are similar, histological findings are crucial for distinction.
  • [MeSH-major] Incidental Findings. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271088.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


3. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res; 2010;12(4):R57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Tenascin-C (TNC) is a large extracellular matrix glycoprotein that shows prominent stromal expression in many solid tumours.
  • The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated.
  • The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.
  • Statistical analysis was performed using a nonparametric Mann-Whitney test for comparison of clinicopathological features with levels of TNC expression and using Jonckheere-Terpstra trend analysis for association of expression with tumour grade.
  • AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts.
  • Although not tumour specific, AD1 and AD2 expression was significantly more frequent in carcinomas in younger women (age ≤40 years; P < 0.001) and AD1 expression was also associated with oestrogen receptor-negative and grade 3 tumours (P < 0.05).
  • AD1 was found to be incorporated into a tumour-specific isoform, not detected in normal tissues.
  • Overexpression of the TNC-14/AD1/16 isoform significantly enhanced tumour cell invasion (P < 0.01) and growth (P < 0.01) over base levels.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):21-34 [10619858.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1796-800 [8956795.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):205-9 [11857409.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1857-67 [12759243.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Pathol. 2003 Dec;201(4):562-72 [14648659.001]
  • [Cites] Science. 2004 Feb 6;303(5659):775-7 [14764858.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7377-85 [15492259.001]
  • [Cites] N Engl J Med. 1986 Aug 28;315(9):559-63 [3736639.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1483 [1351156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Nucleic Acids Res. 1993 Jan 11;21(1):163-8 [7680113.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] Development. 1994 Mar;120(3):637-47 [7512896.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):539-48 [7518469.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] FEBS Lett. 1994 Sep 26;352(2):216-8 [7523186.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] FEBS Lett. 1996 Jul 8;389(3):304-8 [8766721.001]
  • [Cites] Mol Biol Cell. 1996 Jun;7(6):883-92 [8816995.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):999-1004 [8855965.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Differentiation. 1997 Nov;62(2):71-82 [9404002.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1095-104 [9512505.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):477-83 [10404058.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4615-24 [17855508.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34929-37 [17901052.001]
  • [Cites] Breast Cancer Res. 2007;9(6):404; author reply 405 [18279542.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6942-52 [18757408.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5555-64 [18765548.001]
  • [Cites] Breast Cancer Res. 2009;11(2):R24 [19405959.001]
  • [Cites] J Vis Exp. 2009;(29). pii: 1475. doi: 10.3791/1475 [19620957.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • (PMID = 20678196.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2949648
  •  go-up   go-down


Advertisement
4. Kim J, Roh M, Abdulkadir SA: Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer; 2010 Jun 01;10:248
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The serine/threonine kinase PIM1 has been implicated as an oncogene in various human cancers including lymphomas, gastric, colorectal and prostate carcinomas.
  • However, there has been limited analysis of the tumorigenic potential of Pim1 overexpression in benign and malignant human prostate cancer cells in vivo.
  • METHODS: We overexpressed Pim1 in three human prostate cell lines representing different disease stages including benign (RWPE1), androgen-dependent cancer (LNCaP) and androgen-independent cancer (DU145).
  • RESULTS: Overexpression of Pim1 alone was not sufficient to convert the benign RWPE1 cell to malignancy although it enhanced their proliferation rates when grown as xenografts in vivo.
  • Reporter assays revealed increased c-MYC transcriptional activity in Pim1-expressing cells and mRNA expression profiling demonstrated that a large fraction of c-MYC target genes were also regulated by Pim1 expression.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 May 1;60(9):2335-41 [10811103.001]
  • [Cites] Exp Hematol. 2006 Nov;34(11):1480-9 [17046567.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Chromosoma. 2002 Jul;111(2):80-95 [12111331.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 16;1593(1):45-55 [12431783.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1833-41 [12714522.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1301-9 [13679438.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6151-9 [13679853.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8079-84 [14678956.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1869-75 [14592832.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1838-44 [14981536.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):367-71 [15264249.001]
  • [Cites] FEBS Lett. 2004 Jul 30;571(1-3):43-9 [15280015.001]
  • [Cites] Cancer Res. 1977 Nov;37(11):4049-58 [908039.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Prog Clin Biol Res. 1980;37:115-32 [7384082.001]
  • [Cites] Prog Clin Biol Res. 1980;37:67-84 [7384095.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;105(1):20-3 [6833336.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5228-34 [6616459.001]
  • [Cites] Cell. 1989 Feb 24;56(4):673-82 [2537153.001]
  • [Cites] Nature. 1989 Jul 6;340(6228):61-3 [2786994.001]
  • [Cites] Oncogene. 1991 Nov;6(11):1941-8 [1658705.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1215-23 [9214605.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18659-66 [10373478.001]
  • [Cites] Anticancer Drugs. 2007 Feb;18(2):161-70 [17159602.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):932-44 [17643117.001]
  • [Cites] Mol Cancer Ther. 2007 Sep;6(9):2399-408 [17876039.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5076-85 [18593906.001]
  • [Cites] PLoS One. 2008;3(7):e2572 [18596907.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4809-19 [18438430.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2144-51 [18715779.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25 [18509642.001]
  • [Cites] PLoS Genet. 2009 Jul;5(7):e1000542 [19578399.001]
  • [Cites] Oncogene. 2009 Dec 3;28(48):4261-71 [19749799.001]
  • [Cites] Oncogene. 2010 Apr 29;29(17):2477-87 [20140016.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48319-28 [15319445.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):6130-7 [15525646.001]
  • [Cites] J Pathol. 2005 May;206(1):87-91 [15809970.001]
  • [Cites] Mol Cancer Res. 2005 Aug;3(8):443-51 [16123140.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40568-77 [16221667.001]
  • [Cites] Leukemia. 2006 Mar;20(3):539-42 [16437153.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):285-8 [16505280.001]
  • [Cites] Nat Med. 2001 Jan;7(1):101-7 [11135623.001]
  • (PMID = 20515470.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA123484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; 0 / AR protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Thiazoles; EC 2.7.11.1 / Proto-Oncogene Proteins c-pim-1
  • [Other-IDs] NLM/ PMC2886047
  •  go-up   go-down


5. Riddle ND, Quigley BC, Browarsky I, Bui MM: Leiomyosarcoma arising in the pancreatic duct: a case report and review of the current literature. Case Rep Med; 2010;2010:252364
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Context. Leiomyosarcomas are rare malignant smooth muscle tumors that may arise in any organ or tissue that contains smooth muscle, commonly within the gastrointestinal tract.
  • They are most often found in the stomach, large and small intestines, and retroperitoneum.
  • Case Report. This case was diagnosed in a large, tertiary care center in Tampa, Florida.
  • A mass in the tail of the pancreas was identified with large pleomorphic and spindle-shaped cells.
  • The tumor clearly originated from the pancreatic duct wall, filled and expanded the duct lumen, and was covered with a layer of benign biliary epithelium.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tunis Med. 2005 May;83(5):288-91 [16044903.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1720-3 [7370927.001]
  • [Cites] Curr Surg. 2004 Nov-Dec;61(6):572-5 [15590026.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):548-51 [15661250.001]
  • [Cites] Urol Oncol. 2005 Jan-Feb;23(1):22-6 [15885579.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1226-9 [16343220.001]
  • [Cites] Urology. 2006 Feb;67(2):424.e13-424.e15 [16461113.001]
  • [Cites] J Foot Ankle Surg. 2006 Mar-Apr;45(2):127-30 [16513508.001]
  • [Cites] No Shinkei Geka. 2006 Apr;34(4):409-13 [16613223.001]
  • [Cites] Int Surg. 2005 Nov-Dec;90(5):262-5 [16625943.001]
  • [Cites] Cancer Radiother. 2006 May;10(3):137-41 [16330234.001]
  • [Cites] Pathol Int. 2006 Aug;56(8):466-70 [16872443.001]
  • [Cites] Actas Urol Esp. 2006 Jun;30(6):638-40 [16921844.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Oct;263(10):929-34 [16804717.001]
  • [Cites] Arch Esp Urol. 2006 Sep;59(7):728-31 [17078398.001]
  • [Cites] Arch Esp Urol. 2006 Nov;59(9):908-10 [17190216.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):628-33 [17451590.001]
  • [Cites] Dermatol Surg. 2007 May;33(5):634-7 [17451591.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):963-77 [17574946.001]
  • [Cites] Obstet Gynecol Surv. 2007 Jul;62(7):480-6 [17572920.001]
  • [Cites] World J Gastroenterol. 2008 May 14;14(18):2942-5 [18473429.001]
  • [Cites] Pancreas. 2008 Aug;37(2):230-1 [18665093.001]
  • [Cites] Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):158-61 [18720751.001]
  • [Cites] Korean J Radiol. 2007 Nov-Dec;8(6):541-4 [18071285.001]
  • [Cites] HPB (Oxford). 2002;4(3):145-8 [18332943.001]
  • [Cites] Radiat Med. 1999 May-Jun;17(3):239-41 [10440114.001]
  • [Cites] Abdom Imaging. 1999 May-Jun;24(3):299-300 [10227898.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2352-8 [10357405.001]
  • [Cites] Clin Lab Haematol. 1999 Jun;21(3):219-24 [10448606.001]
  • [Cites] Int J Pancreatol. 1999 Dec;26(3):193-9 [10732297.001]
  • [Cites] Int J Clin Oncol. 2004 Jun;9(3):189-92 [15221604.001]
  • [Cites] Rev Esp Enferm Dig. 2004 Apr;96(4):286-7 [15259151.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):433-4 [15332041.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Sep;34(6):690-2 [16053897.001]
  • (PMID = 20589089.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2892659
  •  go-up   go-down


6. Krause E, Gürkov R, Klauss V: [Solitary fibrous tumor in the orbit. Case report and review of the literature]. HNO; 2009 Feb;57(2):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumor in the orbit. Case report and review of the literature].
  • [Transliterated title] Solitärer fibröser Tumor in der Orbita. Fallbericht und Literaturübersicht.
  • BACKGROUND: Solitary fibrous tumor (SFT) is a mesenchymal neoplasm with a benign growth behavior.
  • CASE REPORT: We report on a 94-year-old female patient with a large intraorbital SFT on the left side.
  • Tumor growth over 7 years led to a severe exophthalmos with loss of vision.
  • CONCLUSION: SFT is a rare differential diagnosis of orbital lesions and can be appropriately treated by surgical resection.
  • [MeSH-major] Blindness / etiology. Blindness / prevention & control. Orbital Neoplasms / complications. Orbital Neoplasms / surgery. Solitary Fibrous Tumors / complications. Solitary Fibrous Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eye (Lond). 2001 Feb;15(Pt 1):102-4 [11318269.001]
  • [Cites] Neuropathology. 2006 Dec;26(6):557-63 [17203593.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 May;34(3):331-3 [15741045.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1241-5 [11846919.001]
  • [Cites] HNO. 2006 Dec;54(12):962-6 [16477466.001]
  • [Cites] HNO. 2007 Apr;55(4):287-92 [16622693.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12 ):1501-11 [9850176.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Mar;75(3):363-72 [633933.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Eye (Lond). 1996;10 ( Pt 3):396-9 [8796170.001]
  • [Cites] Orbit. 2006 Mar;25(1):45-50 [16527776.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Korean J Radiol. 2005 Jul-Sep;6(3):136-42 [16145288.001]
  • [Cites] Can J Ophthalmol. 1997 Dec;32(7):432-5 [9435973.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):445-53 [9230909.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1424-8 [11684960.001]
  • [Cites] Surv Ophthalmol. 2003 Sep-Oct;48(5):544-54 [14499820.001]
  • (PMID = 19221826.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 18
  •  go-up   go-down


7. Hardisson D, Regojo RM, Mariño-Enríquez A, Martínez-García M: Signet-ring stromal tumor of the ovary: report of a case and review of the literature. Pathol Oncol Res; 2008 Sep;14(3):333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring stromal tumor of the ovary: report of a case and review of the literature.
  • Signet-ring stromal tumor of the ovary is extremely rare, with only ten cases reported in the literature.
  • We report on a case of signet-ring stromal tumor of the left ovary in a 54-year-old woman who presented with abdominal discomfort.
  • Histologically, the tumor was composed of an admixture of spindle and round cells which contained a large cytoplasmic vacuole which displaced the nucleus, creating a signet-ring appearance.
  • Immunohistochemically, the tumor cells showed positivity for vimentin, actin, inhibin, and calretinin, thus confirming the ovarian stromal origin of the neoplasm.
  • Signet-ring tumor of the ovary is a rare variant of benign ovarian stromal neoplasm and should be distinguished from metastatic mucin-secreting signet-ring adenocarcinoma.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Stromal Cells / pathology
  • [MeSH-minor] Actins / metabolism. Biomarkers, Tumor / metabolism. Calbindin 2. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Diagnosis, Differential. Female. Humans. Inhibins / metabolism. Middle Aged. S100 Calcium Binding Protein G / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(4):333-6 [8389502.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jan-Feb;13(1):90-3 [12631228.001]
  • [Cites] Cancer. 1976 Jul;38(1):166-72 [181127.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):323-6 [10785488.001]
  • [Cites] Histopathology. 2001 May;38(5):403-8 [11422476.001]
  • [Cites] Ultrastruct Pathol. 1995 Sep-Oct;19(5):401-19 [7483017.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):584-90 [12808064.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):45-51 [14668550.001]
  • (PMID = 18758997.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 57285-09-3 / Inhibins
  • [Number-of-references] 8
  •  go-up   go-down


8. Shirodkar SP, Lokeshwar VB: Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther; 2008 Jul;8(7):1111-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?
  • Currently, the detection of initial tumors and recurrent disease is based on evaluation of voided urinary specimens, often followed by cystoscopy.
  • As a result, intense work is being done in the field of bladder tumor markers with the goal of identifying bladder cancer earlier, both in the initial diagnosis and in recurrences of known tumor.
  • The possibility of identifying a marker that could noninvasively differentiate benign and malignant causes of hematuria, and identify recurrences prior to their pathologic progression is the objective of this area of research.
  • Currently, a large number of tumor markers exist, each scrutinized in both the laboratory and in clinical trials.
  • Some novel modalities for tumor detection are also presented.
  • Studies continue to refine the role of these markers in clinical practice, but their ultimate efficacy will need to be borne out in large-scale clinical trials in a multitude of settings.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Hematuria / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / urine. Cystoscopy. Humans. Molecular Diagnostic Techniques / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2007;13(3):187-94 [17922047.001]
  • [Cites] J Urol. 2007 Jan;177(1):80-3 [17162008.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):53-61 [10696245.001]
  • [Cites] Int J Oncol. 1993 Oct;3(4):559-63 [21573400.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):35-63 [16399415.001]
  • [Cites] Urology. 2000 Nov 1;56(5):793-7 [11068304.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):469-71 [8102431.001]
  • [Cites] Eur Urol. 1999 Jan;35(1):52-6 [9933795.001]
  • [Cites] World J Urol. 2008 Feb;26(1):59-65 [17962949.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1701-7 [16541433.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):61-72 [12115318.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):369-73 [14663639.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):884-94 [7666477.001]
  • [Cites] Cancer Pract. 2002 Nov-Dec;10(6):311-22 [12406054.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):52-4 [2045253.001]
  • [Cites] JAMA. 2005 Feb 16;293(7):810-6 [15713770.001]
  • [Cites] J Urol. 2007 Apr;177(4):1277-82; discussion 1282 [17382711.001]
  • [Cites] Urol Oncol. 2006 Nov-Dec;24(6):528-37 [17138134.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):817-24 [15257544.001]
  • [Cites] J Urol. 2003 Jan;169(1):86-9 [12478110.001]
  • [Cites] J Urol. 2007 Feb;177(2):437-43 [17222605.001]
  • [Cites] Urology. 2001 Apr;57(4):680-4 [11306380.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):699-703 [8976763.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2173-9 [17029275.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):293-7 [12209982.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2511-20 [9796985.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):621-30 [14745881.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):299-305 [16418465.001]
  • [Cites] Urology. 2000 Aug 1;56(2):228-31 [10925083.001]
  • [Cites] Urology. 2003 Jan;61(1):243-7 [12559316.001]
  • [Cites] World J Urol. 2004 Jun;22(2):145-9 [14991320.001]
  • [Cites] J Urol. 1998 Feb;159(2):394-8 [9649246.001]
  • [Cites] Chin Med J (Engl). 2006 Nov 5;119(21):1763-71 [17097029.001]
  • [Cites] J Urol. 2006 Sep;176(3):919-26; discussion 926 [16890655.001]
  • [Cites] World J Urol. 2006 Sep;24(4):418-22 [16688457.001]
  • [Cites] J Urol. 2002 Nov;168(5):1950-4 [12394683.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):634-9 [10953114.001]
  • [Cites] J Urol. 2001 Oct;166(4):1280-5 [11547058.001]
  • [Cites] J Urol. 1999 Jul;162(1):53-7 [10379739.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):405-9 [17611663.001]
  • [Cites] J Urol. 2006 Jun;175(6):2032-7; discussion 2037 [16697794.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] World J Urol. 2008 Feb;26(1):45-50 [18180926.001]
  • [Cites] Urology. 2006 Mar;67(3 Suppl 1):25-33; discussion 33-4 [16530072.001]
  • [Cites] Curr Opin Genet Dev. 1991 Dec;1(4):538-43 [1822287.001]
  • [Cites] Semin Diagn Pathol. 1997 May;14(2):123-32 [9179973.001]
  • [Cites] Can J Urol. 1997 Sep;4(3):400-405 [12735818.001]
  • [Cites] Urology. 1998 Nov;52(5):793-6 [9801101.001]
  • [Cites] Med Sci Monit. 2003 Apr;9(4):PI25-9 [12709681.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5352-8 [18048815.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4464-70 [10485499.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jun;134(6):659-65 [18026991.001]
  • [Cites] Urology. 2004 Feb;63(2):392-7 [14972509.001]
  • [Cites] Urology. 2005 Dec;66(6):1256-60 [16360453.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1356-62 [15717321.001]
  • [Cites] BJU Int. 2006 Nov;98(5):1090-3 [17034609.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1280-5 [16287445.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):171-9 [11801555.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):100-4 [15761870.001]
  • [Cites] J Urol. 2000 Jan;163(1):348-56 [10604388.001]
  • [Cites] J Urol. 1996 Oct;156(4):1280-5 [8808854.001]
  • [Cites] Front Biosci. 2002 Jan 01;7:e27-32 [11779714.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):67-72 [11668480.001]
  • [Cites] ScientificWorldJournal. 2006 Mar 27;6:2617-25 [17619739.001]
  • [Cites] Semin Cancer Biol. 1996 Feb;7(1):15-24 [8695762.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Ann Clin Lab Sci. 2006 Winter;36(1):31-8 [16501234.001]
  • [Cites] Am Fam Physician. 2001 Mar 15;63(6):1145-54 [11277551.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):588-97 [12697851.001]
  • [Cites] Asian J Androl. 2007 Sep;9(5):711-5 [17712491.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):845-52 [12808119.001]
  • [Cites] BJU Int. 2008 Jan;101(1):26-9 [17850364.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):83-9 [15389253.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2):75-84 [17382791.001]
  • [Cites] BJU Int. 2007 Feb;99(2):281-5 [17155984.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Mar;173(2):131-5 [17321328.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Urology. 2003 Nov;62(5):952-7 [14624933.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):274-80 [15900578.001]
  • [Cites] Urol Int. 2001;66(4):185-90 [11385303.001]
  • [Cites] J Natl Cancer Inst. 1997 May 21;89(10):724-30 [9168188.001]
  • [Cites] Eur Urol. 1990;17(4):281-5 [2364965.001]
  • [Cites] Nat Med. 1997 Jun;3(6):621-4 [9176487.001]
  • [Cites] Urol Oncol. 2001 Jul;6(4):163-169 [11418323.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1106-13 [17311310.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):295-301 [17210520.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):1971-4 [9817302.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14 [11894002.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 1):1068-72 [17644139.001]
  • [Cites] Urology. 2001 Sep;58(3):367-71 [11549482.001]
  • [Cites] World J Urol. 2007 Dec;25(6):563-71 [17710407.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):49-60 [17275177.001]
  • [Cites] World J Urol. 2000 Dec;18(6):401-5 [11204258.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2618-25 [10914702.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1384-91 [14977841.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2914-22 [12115379.001]
  • [Cites] Urology. 2007 Sep;70(3):482-6 [17905101.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Urology. 2007 Sep;70(3):449-53 [17688921.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1321-6 [16596205.001]
  • [Cites] Urol Clin North Am. 1998 Nov;25(4):661-76 [10026773.001]
  • [Cites] World J Urol. 2008 Feb;26(1):31-7 [18075743.001]
  • [Cites] Blood. 1995 May 1;85(9):2315-20 [7727765.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):329-38 [17373664.001]
  • [Cites] Pharmacoeconomics. 2003;21(18):1315-30 [14750899.001]
  • [Cites] Urology. 2000 Feb;55(2):223-6 [10688083.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):25-37 [10696242.001]
  • [Cites] J Urol. 1999 May;161(5):1486-9 [10210378.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):951-6; discussion 956 [16257108.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2052-6 [16249419.001]
  • [Cites] Indian J Med Sci. 2005 Jun;59(6):235-42 [15988093.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):352-7 [17762630.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1388-96 [17466450.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5519-27 [17158537.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):1-8 [18090481.001]
  • [Cites] J Urol. 2007 Jul;178(1):57-61 [17574060.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2333-40 [10873084.001]
  • [Cites] Isr Med Assoc J. 2002 Mar;4(3):174-5 [11908255.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1423-7 [3304614.001]
  • [Cites] Med Clin North Am. 2004 Mar;88(2):329-43 [15049581.001]
  • [Cites] Int J Urol. 2007 Feb;14(2):108-11 [17302565.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):248-53 [1717095.001]
  • [Cites] J Urol. 2004 Sep;172(3):1123-6 [15311054.001]
  • [Cites] Med Sci Monit. 2003 Aug;9 Suppl 3:25-8 [15156607.001]
  • [Cites] Urology. 2004 Dec;64(6):1121-6 [15596183.001]
  • [Cites] J Urol. 1999 Feb;161(2):443-6 [9915422.001]
  • [Cites] J Urol. 2007 Feb;177(2):481-7; discussion 487 [17222615.001]
  • [Cites] Urology. 1989 Feb;33(2):89-96 [2916296.001]
  • [Cites] Tumour Biol. 2007;28(2):57-62 [17259754.001]
  • [Cites] Eur Urol. 2004 Oct;46(4):466-71 [15363562.001]
  • (PMID = 18588456.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072821; United States / NCI NIH HHS / CA / 5R01 CA-72821-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Number-of-references] 136
  •  go-up   go-down


9. Dilsiz A, Aydin T, Gursan N: Capillary hemangioma as a rare benign tumor of the oral cavity: a case report. Cases J; 2009;2:8622
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capillary hemangioma as a rare benign tumor of the oral cavity: a case report.
  • INTRODUCTION: Hemangioma is a relatively common benign proliferation of blood vessels that primarily develops during childhood.
  • Cavernous hemangioma appears as an elevated lesion of a deep red color, and consists of large dilated sinuses filled with blood.
  • Early detection and biopsy is necessary to determine the clinical behavior of the tumor and potential dentoalveolar complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1992 Dec;110(12):1743-7 [1463416.001]
  • [Cites] Cases J. 2009;2(1):80 [19161627.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Sep;70(3):268-73 [2216353.001]
  • [Cites] J Periodontol. 1974 Aug;45(8):601-7 [4529305.001]
  • [Cites] J Periodontol. 1973 Sep;44(9):579-82 [4543218.001]
  • [Cites] Am J Surg Pathol. 1980 Oct;4(5):470-9 [7435775.001]
  • [Cites] Ann Plast Surg. 2000 Feb;44(2):188-94 [10696047.001]
  • [Cites] Neuroradiology. 2000 Mar;42(3):215-7 [10772147.001]
  • [Cites] Int J Paediatr Dent. 2000 Jun;10(2):161-5 [11310103.001]
  • [Cites] Br J Oral Maxillofac Surg. 2002 Dec;40(6):497-503 [12464208.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):339-44 [12478482.001]
  • [Cites] Acta Chir Plast. 2003;45(2):55-60 [12921261.001]
  • [Cites] Pediatr Surg Int. 2003 Nov;19(9-10):639-45 [14600772.001]
  • [Cites] J Craniofac Surg. 2004 Jan;15(1):82-3 [14704569.001]
  • [Cites] Pediatr Dent. 2007 May-Jun;29(3):239-42 [17688022.001]
  • [Cites] J Periodontol. 2008 Mar;79(3):549-55 [18315439.001]
  • [Cites] Pediatr Clin North Am. 1991 Aug;38(4):811-34 [1870907.001]
  • (PMID = 20181211.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827094
  •  go-up   go-down


10. Haass NK, Smalley KS: Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther; 2009;13(5):283-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.
  • Diagnosis is typically made on the basis of histopathologic criteria; with tumor thickness (Breslow), invasion level (Clark), ulceration, and the extent of lymph node involvement being important prognostic indicators.
  • However, histologic criteria alone cannot diagnose all melanomas and there are often problems in distinguishing subsets of benign nevi from melanoma.
  • The advent of large-scale genomic profiling of melanoma is revealing considerable heterogeneity, suggesting that melanomas could be subgrouped according to their patterns of oncogenic mutation and gene expression.
  • In this review, we discuss the utility of melanoma biomarkers for diagnosis and prognosis and suggest how novel molecular signatures can help guide both melanoma diagnosis and therapy selection.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Melanoma / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14 ):5895-900 [17392427.001]
  • [Cites] J Cell Biol. 1995 Mar;128(5):959-68 [7876319.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3459-71 [15735667.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1398-405 [15846297.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):3112-21 [18790789.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1265-8 [18813315.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):1104 [12072090.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9375-83 [19010912.001]
  • [Cites] Ann Surg. 1970 Nov;172(5):902-8 [5477666.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8048-56 [16258103.001]
  • [Cites] Int J Cancer. 1988 Nov 15;42(5):748-59 [2846449.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):785-7 [17576947.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):294-7 [15549090.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1693-700 [15751018.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Dec;5(12 ):737-40 [18936790.001]
  • [Cites] Semin Cancer Biol. 2005 Dec;15(6):451-9 [16043361.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5743-52 [18632627.001]
  • [Cites] Skin Pharmacol Physiol. 2009;22(2):114-21 [19188759.001]
  • [Cites] Histol Histopathol. 2009 May;24(5):643-50 [19283671.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1708-16 [12175686.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12 ):4901-9 [11406569.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):549-55 [16506207.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):452-74 [19318635.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):273-85 [15986137.001]
  • [Cites] Mod Pathol. 2004 Aug;17 (8):990-7 [15133476.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):756-9 [12591721.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] J Biol Chem. 2006 Sep 1;281(35):25644-51 [16815849.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2046-51 [18421059.001]
  • [Cites] Br J Dermatol. 2001 Aug;145(2):203-9 [11531780.001]
  • [Cites] J Cell Sci. 1994 Apr;107 ( Pt 4):983-92 [8056851.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):150-60 [10102344.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Mol Pathol. 1999 Jun;52(3):151-7 [10621837.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):537-46 [11485912.001]
  • [Cites] Pigment Cell Res. 2005 Jun;18(3):150-9 [15892711.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):945-7 [16619010.001]
  • [Cites] Br J Surg. 2002 Oct;89(10):1223-7 [12296887.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2260-6 [12796394.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1800-4 [10766161.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1473-82 [15735123.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1563-8 [7535342.001]
  • [Cites] Am J Clin Pathol. 1998 Dec;110(6):753-7 [9844587.001]
  • [Cites] Cancer Lett. 2007 Apr 8;248(1):68-80 [16822608.001]
  • [Cites] J Pathol. 1993 Aug;170(4):429-34 [8105045.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S75-81 [9578420.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):805-13 [9502422.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1307-17 [17005948.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):775-6 [17576945.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):309-18 [15339050.001]
  • [Cites] Neuron. 1996 Oct;17(4):587-93 [8893017.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7726-32 [19047099.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7002-10 [15466193.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4340-6 [16908931.001]
  • [Cites] Plast Reconstr Surg. 2005 Feb;115(2):367-75 [15692338.001]
  • [Cites] Bioessays. 2001 Apr;23(4):311-8 [11268036.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):337-41 [15009714.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2872-8 [19336517.001]
  • [Cites] Cell. 1994 Nov 18;79(4):551-5 [7954821.001]
  • [Cites] Exp Cell Res. 1994 Sep;214(1):231-41 [7915992.001]
  • [Cites] Clin Dermatol. 2009 Jan-Feb;27(1):75-102 [19095155.001]
  • [Cites] Oncogene. 2004 Aug 19;23(37):6292-8 [15208680.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23 (23 ):5281-93 [16009947.001]
  • [Cites] Br J Dermatol. 2007 Dec;157(6):1212-6 [17970806.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7234-42 [16243793.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]
  • [Cites] J Histochem Cytochem. 2006 Feb;54(2):171-82 [16046668.001]
  • [Cites] J Cutan Pathol. 2004 Jan;31(1):1-7 [14675278.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] Cancer Lett. 2003 Jan 28;189(2):237-47 [12490317.001]
  • [Cites] Cell Tissue Res. 1999 Nov;298(2):261-73 [10571115.001]
  • [Cites] J Immunol. 1993 Dec 15;151(12):7224-32 [7903103.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2107-15 [11395388.001]
  • [Cites] J Mol Med (Berl). 1996 Jan;74(1):13-33 [8834767.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3 [18510589.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):743-75; quiz 775-8 [15858465.001]
  • [Cites] Clin Chim Acta. 2006 May;367(1-2):28-35 [16480699.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4358-69 [9687504.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):565-72 [19147570.001]
  • [Cites] Cancer Res. 1987 Feb 1;47(3):841-5 [3542195.001]
  • [Cites] Cancer Res. 1990 Feb 15;50(4):1271-8 [1967552.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2514-20 [8162602.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1841-50 [15920168.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1243-53 [16628254.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):188-94 [9627715.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1781-7 [15509546.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2295-303 [9187135.001]
  • [Cites] J Membr Biol. 2007 Aug;218(1-3):29-37 [17581693.001]
  • [Cites] Oncogene. 2007 Nov 29;26(54):7560-8 [17546049.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4182-90 [16618740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24 [19251651.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):664-73 [18245465.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2530-6 [12011132.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1163-9 [16254105.001]
  • [Cites] Eur J Cell Biol. 2004 Dec;83(11-12):647-54 [15679109.001]
  • [Cites] J Natl Cancer Inst. 1995 Mar 1;87(5):366-71 [7531774.001]
  • [Cites] Cancer Res. 1969 Mar;29(3):705-27 [5773814.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):472-82 [16595783.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Biol. 1996 Feb;132(3):475-85 [8636223.001]
  • [Cites] J Cutan Pathol. 2008 May;35(5):433-44 [18399807.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6268-72 [19332774.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3835-40 [9288796.001]
  • [Cites] Curr Oncol Rep. 2008 Sep;10(5):439-46 [18706274.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23 ):11463-9 [18056475.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1293-301 [15140234.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1541-54 [15855653.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3241-4 [19351826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(24):9891-5 [2602381.001]
  • [Cites] J Invest Dermatol. 2007 Nov;127(11):2516-24 [17934503.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:119-46 [9442870.001]
  • [Cites] Br J Dermatol. 2001 Aug;145(2):210-6 [11531781.001]
  • [Cites] Oncogene. 1996 Dec 5;13(11):2339-47 [8957075.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2338-42 [15059882.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):445-9 [17245336.001]
  • [Cites] Mol Biol Cell. 2004 Oct;15(10):4597-608 [15282340.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2876-83 [18790768.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2003-12 [18323787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):641-4 [2643120.001]
  • [Cites] Mol Cell Biol. 1985 Mar;5(3):582-5 [3887133.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):230-9 [18172275.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):745-51 [9284823.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1554-60 [9108459.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):365-70 [11756660.001]
  • [Cites] PLoS Med. 2008 Jun 3;5(6):e120 [18532874.001]
  • [Cites] Nat Clin Pract Oncol. 2009 Feb;6(2):105-17 [19107110.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2008;61(3):265-71 [17569608.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):496-505 [16880792.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):769-74 [9398060.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14 [16361544.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):30171-80 [17693411.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12 (9):2699-710 [11553709.001]
  • [Cites] Melanoma Res. 1996 Apr;6(2):127-31 [8791270.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):95-105 [8814997.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Nov;10(2):153-63 [16358819.001]
  • [Cites] J Cutan Pathol. 2008 Nov;35 Suppl 2:1-10 [18976412.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2628-30 [1348968.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2199-208 [19307507.001]
  • (PMID = 19791833.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 148
  •  go-up   go-down


11. Schäfer H, Baldus SE, Hölscher AH: Giant adenomas of the rectum: complete resection by transanal endoscopic microsurgery (TEM). Int J Colorectal Dis; 2006 Sep;21(6):533-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Large sessile adenomas of the rectum, with a diameter greater than 5 cm, have a high risk to undergo malignant transformation.
  • Transanal endoscopic microsurgery (TEM) offers an alternative operation method to low-anterior rectum resection in this potentially benign tumor situation.
  • A total of 33 patients met the criteria and were analyzed for postoperative complications, histology, and incidence of occult adenocarcinoma; residual tumor status; and tumor recurrence.
  • The residual adenoma status was 18% (n=6), especially in patients with tumors sizes more than 30 cm2.
  • In case of adenoma recurrence (n=4, 12%), a conventional transanal excision (Parks) was applicable, as these tumors were mostly located within the suture-line region of the lower rectum.
  • In case of advanced tumors (1xpT2, 1xpT3), anterior rectum resection was carried out, whereas for the early tumors (2xpT1 low risk, 1x1 pTis), no further therapy was added.
  • CONCLUSION: TEM is an alternative method for the resection of large benign rectal tumors located in the mid- and upper third of the rectum.
  • [MeSH-major] Adenoma / surgery. Colonoscopy / methods. Microsurgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1987 Jan;153(1):41-7 [3799891.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1021-6 [15789125.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):255-9 [15273549.001]
  • [Cites] Dis Colon Rectum. 1995 Mar;38(3):233-8 [7882783.001]
  • [Cites] Surg Endosc. 1995 Oct;9(10):1106-12 [8553213.001]
  • [Cites] Int J Colorectal Dis. 2003 Mar;18(2):131-5 [12548415.001]
  • [Cites] Proc R Soc Med. 1974 Jun;67(6 Pt 1):451-7 [4853754.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):86-9 [14702647.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):S41-4 [12929053.001]
  • [Cites] Curr Top Pathol. 1990;81:277-93 [2407443.001]
  • [Cites] Am Surg. 1998 Dec;64(12):1170-3 [9843338.001]
  • [Cites] Br J Surg. 1973 Sep;60(9):688-95 [4582241.001]
  • [Cites] Am J Surg. 1997 May;173(5):383-5 [9168071.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):65-71 [3337563.001]
  • [Cites] Am J Surg. 1976 Feb;131(2):185-91 [175719.001]
  • [Cites] Am J Surg. 1975 Dec;130(6):729-32 [1200290.001]
  • [Cites] Chirurg. 2005 Apr;76(4):379-84 [15502890.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):183-8 [8857131.001]
  • [Cites] Gastrointest Endosc. 1984 Feb;30(1):18-20 [6706083.001]
  • [Cites] Surg Clin North Am. 1997 Feb;77(1):229-39 [9092112.001]
  • [Cites] Am J Surg. 1992 Jan;163(1):63-9; discussion 69-70 [1733375.001]
  • (PMID = 16133003.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Hirata T, Otani T, Minamiguchi S: Clear cell tumor of the lung. Int J Clin Oncol; 2006 Dec;11(6):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell tumor of the lung.
  • Clear cell tumor of the lung is a rare benign tumor.
  • We report herein a case of clear cell tumor of the lung.
  • Pathologic examination revealed sheets of large round or polygonal cells with clear cytoplasm and immunoreactive positivity for HMB-45 and vimentin.
  • Investigation with abdominal CT scans showed no evidence of renal disease, and the tumor was diagnosed as clear cell tumor of the lung.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1989 Jul-Aug;33(4):511-5 [2750440.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Apr;25(4):652-4 [15037292.001]
  • [Cites] Chirurg. 2003 Jul;74(7):683-6 [12883798.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1242-7 [9331299.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):199-202 [2025321.001]
  • [Cites] Arch Pathol Lab Med. 1991 Oct;115(10):1034-8 [1898230.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Jul;33(7):765-70 [7564005.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):644-53 [1711793.001]
  • [Cites] Surg Today. 1998;28(9):985-7 [9744416.001]
  • [Cites] Yale J Biol Med. 1971 Feb-Apr;43(4-5):213-22 [5578741.001]
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):730-1 [8623676.001]
  • [Cites] Radiology. 1978 Dec;129(3):595-6 [725030.001]
  • (PMID = 17180518.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Nermoen I, Følling I, Vegge K, Larmo A, Nedrebø BG, Husebye ES, Løvås K: Two adults with adrenal myelolipoma and 21-hydroxylase deficiency. Case Rep Med; 2009;2009:916891
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The masses were not removed since myelolipomas are considered benign tumors, and the tumor size did not increase during four- and nine-year observation periods.
  • An adrenal myelolipoma is an important exception to the rule that large tumours should be removed.
  • CAH should be considered as a differential diagnosis of patients with adrenal masses or adrenal myelolipomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2009 Mar-Apr;61(2):231-6 [19536999.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jun;56(6):811-6 [12072053.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Mar;93(3):653-60 [18326005.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):522-6 [17705067.001]
  • [Cites] N Engl J Med. 2007 Feb 8;356(6):601-10 [17287480.001]
  • [Cites] Int J Urol. 2006 Jun;13(6):801-2 [16834664.001]
  • [Cites] Am J Pathol. 1950 Mar;26(2):211-33 [15406252.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Mar;50(3):343-6 [10435060.001]
  • [Cites] Radiology. 1998 Jul;208(1):87-95 [9646797.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1373-85 [9397452.001]
  • [Cites] Am J Med Sci. 1997 Nov;314(5):338-41 [9365337.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):1776-9 [8626833.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):685-9 [1311000.001]
  • [Cites] Surgery. 1988 Jun;103(6):711-5 [3259731.001]
  • [Cites] Pediatrics. 1981 Aug;68(2):242-6 [6267548.001]
  • [Cites] Int J Urol. 2004 Jun;11(6):416-8 [15157212.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):93-100 [12746567.001]
  • [Cites] Eur J Endocrinol. 2002 Sep;147(3):349-55 [12213672.001]
  • [Cites] Endocr Pathol. 2008 Summer;19(2):122-7 [18618087.001]
  • (PMID = 19724639.001).
  • [ISSN] 1687-9627
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2728610
  •  go-up   go-down


14. Biermann K, Heukamp LC, Büttner R, Zhou H: Uterine tumor resembling an ovarian sex cord tumor associated with metastasis. Int J Gynecol Pathol; 2008 Jan;27(1):58-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine tumor resembling an ovarian sex cord tumor associated with metastasis.
  • Uterine tumors resembling ovarian sex-cord tumors (UTROSCT) are very rare, usually benign uterine tumors, and are probably derived from uterine mesenchymal stem cells.
  • Four years after a diagnosis of UTROSCT of the uterine corpus, the patient developed obstructive ileus due to a large infiltrating tumor within the small bowel with the same morphology and expression pattern as the previously diagnosed UTROSCT.
  • In addition, 2 benign gastrointestinal stromal tumors were detected in the same patient.
  • This case indicates that although the majority of UTROSCT are benign tumors, some of them might undergo malignant transformation and have a metastatic potency.
  • [MeSH-major] Intestinal Neoplasms / secondary. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Gastrointestinal Stromal Tumors / metabolism. Gastrointestinal Stromal Tumors / pathology. Humans. Immunohistochemistry. Intestinal Obstruction / etiology. Intestine, Small / metabolism. Intestine, Small / pathology. Neoplasms, Second Primary / metabolism. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156976.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of XIAP-associated factor 1 in human colorectal cancers.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


16. Nagaike K, Chijiiwa K, Hiyoshi M, Ohuchida J, Kataoka H: Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule. Int J Clin Oncol; 2007 Oct;12(5):388-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule.
  • Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized entity representing a spectrum of benign and malignant neoplasms of the pancreas.
  • Preoperative distinction between benign and malignant IPMNs remains difficult.
  • Reported predictive factors for malignancy are size of the main pancreatic duct, cystic neoplasm, and mural nodule.
  • We report herein the case of a 50-year-old woman in whom a large mural nodule (30 mm) in the dilated main pancreatic duct (16 mm in diameter) was detected by ultrasonography, computed tomography, and endoscopic retrograde cholangiopancreatography.
  • Because the large mural nodule and dilatation of the main pancreatic duct were also detected by endoscopic ultrasonography (EUS) and intraductal ultrasonography (IDUS), the main-duct IPMN was considered to have malignant potential.
  • The resected intraductal tumor appeared polypoid with a broad stalk and comprised a proliferation of mucin-containing columnar epithelial cells with papillary structures without malignant features.
  • The final diagnosis was intraductal papillary mucinous adenoma of the pancreas.
  • The size of the mural nodule and the final diagnosis in this case suggest that the introduction of a novel molecular-biological approach might be necessary for the precise preoperative diagnosis of main-duct IPMN and adequate surgical treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Cystadenoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):164-71 [9717782.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg. 1999 Mar;165(3):223-9 [10231655.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Am Surg. 2001 May;67(5):400-6 [11379635.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • (PMID = 17929124.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Santambrogio L, Nosotti M, Palleschi A, Rosso L, Tosi D, De Simone M, Ciulla MM, Maggioni M, Cioffi U: Solitary fibrous tumor of the pleura presenting with syncope episodes when coughing. World J Surg Oncol; 2008;6:86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura presenting with syncope episodes when coughing.
  • BACKGROUND: Solitary fibrous tumor of the pleura is a rarely encountered clinical entity which may have different clinical pictures.
  • Although the majority of these neoplasms have a benign course, the malignant form has also been reported.
  • The diagnostic work-up including chest x-ray, CT and PET, revealed a large solitary mass of the left hemithorax.
  • Hystological examination of the surgical specimen showed an encapsulated mass measuring 12 x 11.5 x 6 cm consistent with a solitary fibrous tumor of the pleura.
  • CONCLUSION: In our case its resection definitively resolved the episodes of situational syncope due, in our opinion, to the large thoracic mass compressing the phrenic nerve.
  • [MeSH-major] Cough / etiology. Nerve Compression Syndromes / etiology. Phrenic Nerve. Solitary Fibrous Tumor, Pleural / complications. Syncope / etiology

  • MedlinePlus Health Information. consumer health - Cough.
  • MedlinePlus Health Information. consumer health - Fainting.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):40-4 [16788942.001]
  • [Cites] J Am Coll Cardiol. 2006 Jun 20;47(12):2498-503 [16781380.001]
  • [Cites] Ital Heart J. 2005 Mar;6(3):249-55 [15875516.001]
  • [Cites] South Med J. 1990 Jun;83(6):690-4 [2162571.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):111-5 [14720142.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Oct;22(4):640-2 [12297192.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • (PMID = 18713458.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2531110
  •  go-up   go-down


18. Wang W, Feng B, Li X, Yin P, Gao P, Zhao X, Lu X, Zheng M, Xu G: Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst; 2010 Oct;6(10):1947-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.
  • Colorectal carcinoma (CRC) is the third most commonly encountered cancer and fourth cause of cancer-associated death worldwide.
  • In this study both ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and online affinity solid phase extraction-high performance liquid chromatography (SPE-HPLC) were used to analyze the urinary metabolites from 34 healthy volunteers, 34 benign colorectal tumor and 50 colorectal carcinoma patients to produce comprehensive metabolic profiling data.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Colorectal Neoplasms / urine. Mass Spectrometry / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617254.001).
  • [ISSN] 1742-2051
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Rajasekhar G, Mushtaq M, Vura NG, Shekar R, Kumar S: Condyloma acuminatum associated with odontogenic myxoma: a case report. J Maxillofac Oral Surg; 2009 Dec;8(4):384-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Odontogenic myxoma is a rare tumor of jaws which occurs in the tooth-bearing areas of the mandible and maxilla.
  • It is an uncommon, benign, but locally aggressive neoplasm.
  • This case report highlights a 17-year-old girl with two lesions in oral cavity with soft tissue growth on the palate which has been diagnosed as Condyloma Acuminatum, treated by surgical excision and a large swelling on the right side of the mandible in the same patient diagnosed as odontogenic myxoma where marginal resection was performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Vener Dis. 1978 Dec;54(6):433-40 [581655.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1968 Oct;26(4):434-40 [5244772.001]
  • [Cites] Dermatol Surg. 2003 Mar;29(3):300-3 [12614429.001]
  • [Cites] Int J Oral Maxillofac Surg. 2008 Dec;37(12):1159-61 [18774261.001]
  • [Cites] Br J Vener Dis. 1983 Oct;59(5):325-6 [6311323.001]
  • [Cites] Jpn J Clin Oncol. 1996 Dec;26(6):393-7 [9001342.001]
  • [Cites] Sao Paulo Med J. 1997 Mar-Apr;115(2):1383-9 [9460298.001]
  • [Cites] J Clin Pathol. 1965 Mar;18:142-9 [14276146.001]
  • [Cites] Histopathology. 2004 Mar;44(3):216-21 [14987224.001]
  • [Cites] J Contemp Dent Pract. 2006 Feb 15;7(1):117-24 [16491154.001]
  • [Cites] J Am Dent Assoc. 2003 Mar;134(3):331-4 [12699047.001]
  • (PMID = 23139551.001).
  • [ISSN] 0972-8279
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3454105
  • [Keywords] NOTNLM ; Autoinoculation / Condyloma acuminatum / HPV-6 / Odontogenic myxoma / Palate / Young adult
  •  go-up   go-down


20. Floris G, Deraedt K, Samson I, Brys P, Sciot R: Epithelioid hemangioma of bone: a potentially metastasizing tumor? Int J Surg Pathol; 2006 Jan;14(1):9-15; discussion 16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid hemangioma of bone: a potentially metastasizing tumor?
  • The case of a 15-year-old boy with a severe swelling of the 2nd toe in the left foot and a large swelling of the left inguinofemoral region is described.
  • As such, epithelioid hemangioma might be comparable to another benign vascular tumor, the retiform hemangioendothelioma, which occasionally metastasizes to the lymph nodes without systemic spread.
  • [MeSH-minor] Adolescent. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Diagnosis, Differential. Groin. Humans. Immunohistochemistry. Keratins / analysis. Male. Radiography

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Int J Surg Pathol 14(1):9-15, 2006.
  • (PMID = 16501828.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 68238-35-7 / Keratins
  •  go-up   go-down


21. Reid BJ: Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark; 2010;9(1-6):307-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical management of Barrett's esophagus, like many other "premalignant" conditions, is characterized by overdiagnosis of benign early changes that will not cause death or suffering during the lifetime of an individual and underdiagnosis of life-threatening early disease.
  • A large body of evidence accumulated over several decades implicates chromosome instability in neoplastic progression from Barrett's esophagus to esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1186-96 [17287898.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70 [17431220.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Hum Pathol. 1992 May;23(5):479-82 [1568744.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2946-50 [1581911.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(10):703-10 [1816011.001]
  • [Cites] Gut. 1992 May;33(5):587-91 [1351861.001]
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1769-76 [1360434.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):648-51 [8119224.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2292-5 [8162566.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1589-95 [8194706.001]
  • [Cites] Stat Med. 1994 May 15;13(9):955-68 [8047747.001]
  • [Cites] Gut. 1994 Oct;35(10):1348-51 [7959183.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):151-5 [7816807.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1766-8 [7827934.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:577-83 [7587115.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):334-9; discussion 339-41 [11515862.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2575-83 [11569678.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1179-86 [12439111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16910-5 [12486240.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):683-9 [12753151.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Pathol. 1988 Apr;131(1):53-61 [3354644.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):355-67 [2910757.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):65-71 [2911184.001]
  • [Cites] Lab Invest. 1989 Mar;60(3):418-32 [2927081.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] Gastroenterology. 1989 Oct;97(4):815-20 [2777038.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6332-40 [17452981.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55 [18086770.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7 [18199717.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1303-10 [18000824.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):510-22 [18400571.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1128-35 [18602665.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1280-1 [18772403.001]
  • [Cites] Gut. 2008 Oct;57(10):1354-9 [18424568.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2331-6 [18729198.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Dis Esophagus. 2008;21(6):529-38 [18840137.001]
  • [Cites] Mol Cancer. 2008;7:75 [18831746.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] PLoS One. 2008;3(11):e3809 [19043591.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):809-17 [19229128.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):814-8 [10570342.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95 [10601379.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):555-66 [10666385.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1702-10 [10815888.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Genome Res. 2000 Aug;10(8):1126-37 [10958631.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3164-70 [11306503.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):302-6 [14566848.001]
  • [Cites] Mod Pathol. 2004 May;17(5):588-96 [15017433.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3084-92 [16407829.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40 [17035402.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6637-42 [17121882.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Oct 15;42(2):281-6 [2790761.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):259-63 [8542577.001]
  • [Cites] Oncogene. 1996 May 2;12(9):1873-8 [8649847.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4499-502 [8813147.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):298-304 [8816585.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1867-73 [8934532.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):515-31 [9210354.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1653-9 [9349498.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):641-51 [9708926.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):950-7 [9764589.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Oct 1;106(1):11-7 [9772903.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1862-7 [10430093.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4784-7 [10519384.001]
  • [Cites] Surgery. 1957 Jun;41(6):881-94 [13442856.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] Cancer Lett. 2005 Jan 20;217(2):221-30 [15617840.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):751-60 [15720801.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):830-4 [15824152.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):584-91 [15825175.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1274-81 [16230080.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] J Pathol. 2006 Jan;208(1):100-7 [16278815.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2616-21 [16393209.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6293-300 [17975140.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):683-7 [710836.001]
  • [Cites] Arch Surg. 1983 May;118(5):543-9 [6838359.001]
  • [Cites] Gastroenterology. 1987 Jul;93(1):1-11 [3582897.001]
  • [Cites] Am J Gastroenterol. 1987 Oct;82(10):1012-5 [3661507.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • (PMID = 22112482.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01CA91955
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS578448; NLM/ PMC4026269
  •  go-up   go-down


22. Yoo WH, Kim JR, Jang KY, Lee SY, Park JH: Rapidly developed huge bursitis associated with scapular osteochondroma of the multiple exostosis: a case report. Rheumatol Int; 2009 Jan;29(3):317-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteochondroma is the most common benign bone tumor and present as multiple masses in the hereditary disorder of multiple hereditary exostosis.
  • Large bursa formation with mechanical symptom has been very rarely reported in osteochondroma in which bursa is over the cap.

  • Genetic Alliance. consumer health - Osteochondroma.
  • MedlinePlus Health Information. consumer health - Bursitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1981 May;75(5):648-53 [7234751.001]
  • [Cites] Skeletal Radiol. 1991;20(7):513-6 [1754913.001]
  • [Cites] Clin Orthop Relat Res. 1999 Feb;(359):237-46 [10078149.001]
  • [Cites] Skeletal Radiol. 1990;19(6):465-7 [2120777.001]
  • [Cites] AJR Am J Roentgenol. 1979 Nov;133(5):895-8 [115279.001]
  • [Cites] Acta Orthop Belg. 2006 Dec;72 (6):748-55 [17260614.001]
  • (PMID = 18682954.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Rippe V, Dittberner L, Lorenz VN, Drieschner N, Nimzyk R, Sendt W, Junker K, Belge G, Bullerdiek J: The two stem cell microRNA gene clusters C19MC and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas. PLoS One; 2010;5(3):e9485
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid adenomas are common benign human tumors with a high prevalence of about 5% of the adult population even in iodine sufficient areas.
  • Rearrangements of chromosomal band 19q13.4 represent a frequent clonal cytogenetic deviation in these tumors making them the most frequent non-random chromosomal translocations in human epithelial tumors at all.
  • In depth molecular characterization of the breakpoint in a cell line from one adenoma of this type reveals the existence of large Pol-II mRNA fragments as the most likely source of up-regulation of the C19MC cluster.
  • The up-regulation of the clusters is likely to be causally associated with the pathogenesis of the corresponding tumors.
  • [MeSH-major] Adenoma / genetics. Chromosomes / ultrastructure. Gene Rearrangement. MicroRNAs / genetics. Multigene Family. Stem Cells / cytology. Thyroid Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosomes, Human, Pair 19. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence / methods. Molecular Sequence Data. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2009 Jun;37(10):3464-73 [19339516.001]
  • [Cites] J Transl Med. 2009;7:20 [19309508.001]
  • [Cites] Genome Res. 2010 Mar;20(3):311-9 [20032171.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(1-2):48-51 [11474178.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cytogenet Cell Genet. 2001;95(3-4):189-91 [12063398.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Gene. 2002 Oct 16;299(1-2):195-204 [12459267.001]
  • [Cites] Genome Biol. 2004;5(8):R59 [15287981.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 1;40(1):29-32 [2758398.001]
  • [Cites] Cytometry. 1990;11(1):105-9 [2307050.001]
  • [Cites] Cell Biol Int Rep. 1992 Apr;16(4):339-47 [1326410.001]
  • [Cites] Cancer Genet Cytogenet. 1993 May;67(1):1-6 [8504394.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Oct;20(2):201-3 [9331571.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Feb;101(1):42-8 [9460499.001]
  • [Cites] Gene. 1999 Apr 29;231(1-2):77-86 [10231571.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):48-57 [18167339.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):135-9 [18206539.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):202-10 [18193036.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1506-16 [18403753.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6 [18755890.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] Childs Nerv Syst. 2009 Jan;25(1):13-20 [18818933.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1221-9 [19141645.001]
  • [Cites] J Cell Biochem. 2009 Apr 15;106(6):1020-30 [19229866.001]
  • [Cites] Cancer Cell. 2009 Dec 8;16(6):533-46 [19962671.001]
  • (PMID = 20209130.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GQ334687/ GQ334688
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN371 microRNA, human; 0 / MicroRNAs; 0 / Oncogene Proteins, Fusion
  • [Other-IDs] NLM/ PMC2831057
  •  go-up   go-down


24. Prasad K, Rao SG, Harish K: Giant cell tumor of the temporal bone--a case report. BMC Ear Nose Throat Disord; 2005 Sep 15;5:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the temporal bone--a case report.
  • BACKGROUND: Giant cell tumor is a benign but locally aggressive bone neoplasm which uncommonly involves the skull.
  • The petrous portion of the temporal bone forms a rare location for this tumor.
  • CASE PRESENTATION: The authors report a case of a large giant cell tumor involving the petrous and squamous portions of the temporal bone in a 26 year old male patient.
  • Radical excision of the tumor was achieved but facial palsy could not be avoided.
  • CONCLUSION: Radical excision of skull base giant cell tumor may be hazardous but if achieved is the optimal treatment and may be curative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 2004 Jan;62(1):116-8 [14733232.001]
  • [Cites] Skeletal Radiol. 2005 Apr;34(4):225-8 [15365782.001]
  • [Cites] J Lab Clin Med. 2004 Oct;144(4):193-200 [15514587.001]
  • [Cites] J Orthop Res. 2005 Jan;23(1):203-9 [15607894.001]
  • [Cites] J Neurosurg. 1983 Aug;59(2):322-7 [6864300.001]
  • [Cites] J Orthop Res. 2000 Jul;18(4):647-54 [11052502.001]
  • [Cites] Neuroradiology. 1999 Apr;41(4):305-7 [10344520.001]
  • [Cites] Int J Oncol. 1999 Feb;14(2):291-300 [9917505.001]
  • [Cites] Histopathology. 1979 Nov;3(6):511-22 [511122.001]
  • [Cites] Surg Neurol. 1985 Jan;23(1):25-30 [3964973.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):54-8 [9950250.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):148-51 [8271002.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):924-8 [3572521.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1124-32 [1515987.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Aug;66(2):197-208 [3174054.001]
  • [Cites] Surg Neurol. 1978 Mar;9(3):185-8 [635765.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):117-28 [15972958.001]
  • [Cites] Indian J Cancer. 1991 Dec;28(4):177-80 [1818017.001]
  • [Cites] Surg Neurol. 1986 Jul;26(1):59-62 [3715701.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] Neurosurgery. 1988 Jul;23 (1):120-2 [3173651.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):210-6 [11863217.001]
  • (PMID = 16162299.001).
  • [ISSN] 1472-6815
  • [Journal-full-title] BMC ear, nose, and throat disorders
  • [ISO-abbreviation] BMC Ear Nose Throat Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1253509
  •  go-up   go-down


25. Sieunarine K, Cowie AS, Bartlett JD, Lindsay I, Smith JR: A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique. Int J Gynecol Cancer; 2005 Jul-Aug;15(4):671-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique.
  • Adenomatoid tumors of the uterus are uncommon benign lesions derived from mesothelium, with a prevalence of 1.2% in one study of 1 000 unselected hysterectomy specimens.
  • They are usually small and near the serosal surface; however, they may be large and diffuse (giant adenomatoid tumors).
  • This transpired to be an adenomatoid tumor, and she underwent three transcervical resections of the tumor (TCRT) over a period of 12 months for tumor recurrence and failure of symptom resolution.
  • A specialist opinion on the suitability of vascular embolization of the tumor judged that it would be ineffective for this lesion.
  • She then underwent a Strassman procedure and removal of the adenomatoid tumor.
  • This involved dissection of ureters and pelvic vasculature, selective temporary ligation of uterine arteries, hemisection of the uterus, and excision of the tumor with frozen sections to ensure clear tumor margins and resuturing of the uterine halves.
  • Temporary vascular occlusion of the uterine arteries and ovarian vessels allowed a Strassman procedure, which resulted in successful resection of a recurrent giant adenomatoid tumor of the uterus, with fertility preservation in a young nulliparous woman.
  • Two and a half years on there is no evidence of tumor recurrence.
  • [MeSH-major] Adenomatoid Tumor / surgery. Gynecologic Surgical Procedures / methods. Neoplasm Recurrence, Local / surgery. Uterine Neoplasms / surgery. Uterus / blood supply

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014122.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ozkaya S, Findik S, Demir H, Yuksel C, Atici AG: Polyostotic fibrous dysplasia of the ribs: An unusual cause of chest pain and dyspnea. Int Med Case Rep J; 2009;2:23-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrous dysplasia is a benign bony abnormality that may be monostotic or polyostotic and is not included in the differential diagnosis of chest pain and dyspnea, since it is typically asymptomatic.
  • Chest X-ray and chest computed tomography scan revealed a large solid mass arising from the anterior parts of the left fourth, fifth, and sixth ribs and compressing the adjacent lung parenchyma.
  • The tumor was completely removed surgically and histopathologic examination was consistent with fibrous dysplasia without malignant transformation.
  • This report demonstrates that polyostotic dysplasia of the ribs may cause chest pain and dyspnea and present radiographically as a large mass.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23754878.001).
  • [ISSN] 1179-142X
  • [Journal-full-title] International medical case reports journal
  • [ISO-abbreviation] Int Med Case Rep J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3658210
  • [Keywords] NOTNLM ; chest wall / computed tomography / imaging / thoracotomy
  •  go-up   go-down


27. Vicari RM, Polanco E, Schechtmann N, Santiago JO, Shaurya K, Halstead M, Marszal D, Grosskreutz T, Thareja S: Atrial myxoma presenting with orthostatic hypotension in an 84-year-old Hispanic man: a case report. J Med Case Rep; 2009;3:9328
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Left atrial myxomas remain the most common benign primary cardiac tumors, and these cardiac growths can masquerade as mitral stenosis, infective endocarditis and collagen vascular disease.
  • A transthoracic echocardiogram revealed a large atrial myxoma occupying the majority of the left atrium, with the posterior border of the large atrial mass defined by eccentric mitral regurgitation identified during cardiac catheterization.
  • Left atrial myxoma excision was performed, revealing a 7 x 6.5 x 4.5 cm atrial tumor attached to a 4 x 3 x 2 cm stalk of atrial septal tissue.
  • Two-dimensional echocardiography provides substantial advantages in detecting intracardiac tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1993 Dec;100(6):671-80 [8249916.001]
  • [Cites] Clin Auton Res. 2008 Mar;18 Suppl 1:8-13 [18368301.001]
  • [Cites] Int J Cardiol. 2005 May 11;101(1):115-21 [15860393.001]
  • (PMID = 20062757.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803851
  •  go-up   go-down


28. Walid MS, Heaton RL: Case report of a cervical lipoleiomyoma with an incidentally discovered ovarian granulosa cell tumor - imaging and minimal-invasive surgical procedure. Ger Med Sci; 2010;8:Doc26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of a cervical lipoleiomyoma with an incidentally discovered ovarian granulosa cell tumor - imaging and minimal-invasive surgical procedure.
  • Uterine lipoleiomyomas are rare benign tumors that mostly affect the uterine corpus.
  • We are reporting the imaging and operative procedure of a very rare case of a large lipoleiomyoma of the uterine cervix combined with an occult adult ovarian granulosa cell tumor.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Leiomyoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2006 Jul;25(3):239-42 [16810060.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):439-40 [11874076.001]
  • [Cites] Br J Radiol. 1997 Oct;70(838):1068-70 [9404215.001]
  • [Cites] Abdom Imaging. 2000 Nov-Dec;25(6):655-7 [11029102.001]
  • [Cites] AJR Am J Roentgenol. 2001 Oct;177(4):856 [11566688.001]
  • (PMID = 21063471.001).
  • [ISSN] 1612-3174
  • [Journal-full-title] German medical science : GMS e-journal
  • [ISO-abbreviation] Ger Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2975263
  • [Keywords] NOTNLM ; granulosa cell tumor / lipomeiomyoma / total laparoscopic hysterectomy
  •  go-up   go-down


29. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, Cunha GR: Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer; 2006 May 1;118(9):2123-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In [T+E2]-implanted mice, mUGM+BPH-1 TRs formed carcinomas that contained a fibrous connective tissue stroma permeating the tumor; smooth muscle when present was associated with vasculature.
  • Epithelial cells isolated from untreated mUGM+BPH-1 TRs exhibited benign histology and formed small nontumorigenic grafts when subsequently transplanted into athymic nude mice.
  • In contrast, epithelial cells isolated from mUGM+BPH-1 tumors of [T+E2]-treated hosts formed large tumors that grew independent of stromal and hormonal support and developed lymph node metastases.
  • [MeSH-major] Estradiol / physiology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / physiopathology. Testosterone / physiology
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Disease Progression. Epithelial Cells / physiology. Humans. Male. Mesoderm. Mice. Mice, Nude. Neoplasm Metastasis. Prostate / cytology. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16331600.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG0026604; United States / NCI NIH HHS / CA / CA84294; United States / NCI NIH HHS / CA / CA89520; United States / NCI NIH HHS / CA / CA96403; United States / NCI NIH HHS / CA / CA97725-01; United States / NICHD NIH HHS / HD / HD007263; United States / NCI NIH HHS / CN / N01CN15114-MAO; United States / NCI NIH HHS / CA / U01 CA96403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol
  •  go-up   go-down


30. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A: Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol; 2007 Oct;9(4):447-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for the use of radiotherapy in the management of a variety of benign intracranial neoplastic and nonneoplastic pathologies are increasing.
  • Although the short-term risks are minimal, the long-term risks of radiation-induced de novo secondary neoplasms or malignant progression of the primary benign tumor need to be considered.
  • There are currently 19 reported cases of tumors linked with stereotactic radiotherapy/radiosurgery, to which we add our second institutional experience of a patient who succumbed to a glioblastoma multiforme (GBM) after stereotactic radiotherapy for an acoustic neuroma (AN).
  • Review of these 20 cases revealed 10 de novo secondary tumors, of which eight were malignant, with six being malignant gliomas.
  • The majority of the cases (14 of 20) involved AN, with most being in patients with neurofibromatosis-2 (NF2; 8 of 14), reflecting the large numbers and long-term use of radiotherapy for AN.
  • Accelerated growth of the primary benign AN, some 2 to 6 years after focused radiotherapy, was found in six of eight NF2 patients, with pathological verification of a malignant nerve sheath tumor documented in most.
  • [MeSH-major] Brain Neoplasms / etiology. Glioblastoma / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neuroma, Acoustic / surgery. Radiosurgery / adverse effects


31. Tse GM, Chaiwun B, Lau KM, Scolyer R, Lee CS, Karim RZ, Putti TC, Law BK, Lui PC, Tan PH: Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours. J Clin Pathol; 2007 Sep;60(9):1051-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Endothelin-1 expression is increased in infiltrating duct carcinoma and is associated with larger tumour size, higher histological grade and lymphovascular permeation.
  • METHOD: A large series of 461 phyllodes tumours (291 benign, 115 borderline malignant and 55 frankly malignant) were evaluated for endothelin-1 expression in both the epithelial cells and stromal cells by immunohistochemistry; results were correlated with the tumour grade.
  • RESULTS: For benign phyllodes tumours, the epithelial staining of endothelin was negative, weak, moderate and strong in 6%, 26%, 15% and 53% of cases respectively; results were 4%, 18%, 19% and 59% respectively for borderline and 6%, 18%, 6% and 70% respectively for frankly malignant tumours.
  • For the stromal staining, the negative, weak, moderate and strong staining was 32%, 19%, 18% and 31% respectively for benign phyllodes, 24%, 13%, 10% and 53% respectively for borderline and 8%, 16%, 17% and 59% respectively for frankly malignant tumours.
  • [MeSH-major] Breast Neoplasms / metabolism. Endothelin-1 / metabolism. Neoplasm Proteins / metabolism. Phyllodes Tumor / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):910-6 [8608483.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nature. 1988 Mar 31;332(6163):411-5 [2451132.001]
  • [Cites] FEBS Lett. 1988 Apr 25;231(2):440-4 [3282927.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):7856-61 [2542249.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] J Surg Oncol. 1990 Sep;45(1):46-51 [2166186.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1741-8 [1701822.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):141-7 [1309302.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):720-7 [9973223.001]
  • [Cites] Pathol Res Pract. 1998;194(2):97-104 [9584322.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4046-9 [1319837.001]
  • [Cites] Eur J Pharmacol. 1999 Jun 30;375(1-3):133-8 [10443571.001]
  • [Cites] Histopathology. 1999 Aug;35(2):162-9 [10460662.001]
  • [Cites] Pathol Int. 1999 Sep;49(9):807-10 [10504552.001]
  • [Cites] Am J Clin Pathol. 2005 Apr;123(4):529-40 [15743740.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):129-38 [15863261.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1720-8 [15841074.001]
  • [Cites] Surg Oncol. 1995;4(6):309-15 [8809953.001]
  • [Cites] Histopathology. 2000 Feb;36(2):161-7 [10672062.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):51-61 [10708518.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Apr;22(4):422-31 [10745023.001]
  • [Cites] BJU Int. 2000 Apr;85 Suppl 2:45-8 [10781185.001]
  • [Cites] Eur J Immunol. 2002 Sep;32(9):2393-400 [12207323.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):21-8 [12497202.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1273-81 [12516960.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Pathol. 2003 May;200(1):59-64 [12692842.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4125-31 [14519635.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1007-13 [14559983.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2461-8 [15059899.001]
  • [Cites] Mod Pathol. 2004 Jul;17(7):827-31 [15044924.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1053-7 [15343505.001]
  • [Cites] Radiology. 1983 Feb;146(2):481-6 [6294737.001]
  • [Cites] J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S1-4 [11078319.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:851-76 [11264479.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):734-40 [12118111.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • (PMID = 17158636.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1972415
  •  go-up   go-down


32. Kumar A, Bhatti SS, Sharma S, Gupta SD, Kumar R: Inflammatory pseudotumor of urinary bladder - a diagnostic and management dilemma. Int Urol Nephrol; 2007;39(3):799-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammatory pseudotumors (IPT) are uncommon, benign, non-epithelial tumors of the urinary bladder.
  • The transititional cell carcinoma constitutes 90% of malignant epithelial tumors of urinary bladder.
  • Large, endoscopically unresectable tumors require radical surgery.
  • IPT resemble such tumors, morphologically, radiologically and clinically.
  • The benign nature of this tumor warrants conservative surgical management, either transurethral resection or partial cystectomy.
  • Awareness of this entity and its inclusion in the differential diagnosis may prevent unnecessary radical surgery.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / surgery. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2003 Jun;143(2):169-71 [12781452.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1233-8 [1463096.001]
  • [Cites] Urology. 1980 Dec;16(6):635-7 [7445316.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8742-8 [14695189.001]
  • [Cites] Am J Surg Pathol. 1985 May;9(5):366-73 [4091176.001]
  • [Cites] Ann Intern Med. 2006 Jan 17;144(2):101-6 [16418409.001]
  • [Cites] Yonsei Med J. 2000 Apr;41(2):273-5 [10817030.001]
  • [Cites] Hum Pathol. 1993 Nov;24(11):1203-10 [7503934.001]
  • [Cites] Br J Surg. 1987 May;74(5):401 [3594137.001]
  • [Cites] N Engl J Med. 2003 Dec 18;349(25):2442-7 [14681511.001]
  • [Cites] J R Soc Med. 1997 Jan;90(1):46-7 [9059384.001]
  • [Cites] J Surg Res. 2002 Apr;103(2):146-52 [11922728.001]
  • [Cites] Lupus. 2004;13(9):635-8 [15485092.001]
  • [Cites] Radiology. 1991 Apr;179(1):66-8 [2006306.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):264-74 [8434707.001]
  • (PMID = 17333528.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


33. Rushing EJ, Cooper PB, Quezado M, Begnami M, Crespo A, Smirniotopoulos JG, Ecklund J, Olsen C, Santi M: Subependymoma revisited: clinicopathological evaluation of 83 cases. J Neurooncol; 2007 Dec;85(3):297-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Subependymomas are rare ependymal neoplasms.
  • To date, a large clinicopathologic study of these benign neoplasms treated with modern neurosurgical techniques has not been reported.
  • Tumors arose in the posterior fossa (n = 43), lateral ventricles (n = 37), spinal cord (2) and only one arose in the temporal horn.
  • Tumors ranged in size from 2.0 mm to 60 mm in greatest dimension (mean, 23.0 mm).
  • Eighteen-percent (15/83) of subependymomas exhibited a mixed histologic pattern; that is, subependymoma together with another glial tumor.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Glioma, Subependymal / pathology. Infratentorial Neoplasms / pathology. Mixed Tumor, Malignant / pathology

  • Genetic Alliance. consumer health - Subependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 1995 Nov-Dec;16(10):2121-9 [8585504.001]
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):518-26 [7622676.001]
  • [Cites] AJR Am J Roentgenol. 1995 Nov;165(5):1245-50 [7572512.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1108-11 [8189269.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):227-87 [14752523.001]
  • [Cites] J Neurosurg. 1983 Dec;59(6):1088-91 [6631507.001]
  • [Cites] Neurosurgery. 2006 May;58(5):881-90; discussion 881-90 [16639322.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):306-9 [10320142.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):25-8 [15803371.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):991-7 [15731777.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 1;108(1):84 [9973931.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):83-91 [2105621.001]
  • [Cites] Pathol Int. 2003 Mar;53(3):169-73 [12608898.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):741-5 [1407461.001]
  • [Cites] J Neurooncol. 2003 Jan;61(1):57-67 [12587796.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):873 [10506435.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):496-505 [9488304.001]
  • [Cites] J Neurosurg. 1978 Nov;49(5):689-96 [712391.001]
  • [Cites] Neurosurgery. 1986 Oct;19(4):594-8 [3785597.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Feb;99(1):17-22 [9107462.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 May;11(3):567-74 [2349896.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):508-12 [3973720.001]
  • (PMID = 17569000.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Koljonen V, Jahkola T, Tukiainen E, Granroth G, Haglund C, Böhling T: Tenascin-C in primary Merkel cell carcinoma. J Clin Pathol; 2005 Mar;58(3):297-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Merkel cell carcinoma (MCC) is a rare malignant cutaneous neuroendocrine tumour that mostly affects the elderly.
  • It shows rapid progression of the primary tumour, together with a vertical growth pattern into the underlying subcutaneous tissue.
  • Tenascin-C (Tn-C) is a large extracellular matrix glycoprotein that is expressed in various benign and malignant processes.
  • The expression of Tn-C correlated significantly with large tumour size.
  • CONCLUSIONS: Tn-C expression seems to increase with tumour size and malignant behaviour.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Merkel Cell / metabolism. Neoplasm Proteins / metabolism. Skin Neoplasms / metabolism. Tenascin / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Division. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jan;31(1):58-62 [10665914.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Forensic Sci Int. 2002 Apr 18;126(2):118-22 [12084487.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):3051-6 [12926160.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):607-10 [12943628.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):31-40 [14618612.001]
  • [Cites] APMIS. 2004 Jan;112(1):39-44 [14961973.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4587-91 [14981900.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Sci Am. 1986 Jun;254(6):42-51 [3010451.001]
  • [Cites] Dev Biol. 1988 Aug;128(2):245-55 [2456233.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):254-6 [2170468.001]
  • [Cites] Br J Dermatol. 1991 Jan;124(1):13-20 [1704250.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):811-6 [1707033.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1143-50 [1719820.001]
  • [Cites] Invasion Metastasis. 1991;11(6):325-31 [1726610.001]
  • [Cites] Development. 1993 Apr;117(4):1183-98 [8404525.001]
  • [Cites] Perspect Dev Neurobiol. 1994;2(1):111-16 [7530137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):315-23 [7836085.001]
  • [Cites] Methods Enzymol. 1994;245:52-61 [7539094.001]
  • [Cites] Int Arch Allergy Immunol. 1995 Aug;107(4):484-90 [7620364.001]
  • [Cites] Int J Cancer. 1996 Dec 20;69(6):445-7 [8980244.001]
  • [Cites] Matrix Biol. 1998 Aug;17(4):305-16 [9749946.001]
  • [Cites] Clin Cancer Res. 1995 Sep;1(9):1035-41 [9816077.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1687-92 [9893653.001]
  • [Cites] Am J Dermatopathol. 1999 Feb;21(1):16-20 [10027519.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):415-21 [10366470.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • (PMID = 15735164.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tenascin
  • [Other-IDs] NLM/ PMC1770604
  •  go-up   go-down


35. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • The diagnosis of an oncocytic adrenal cortical adenoma was made.
  • These extraadrenal tumors are thought to arise from heterotopic adrenocortical tissue in the spinal cavity.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • To date, only five such intraspinal tumors have been observed.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • A view of the literature of these rare but probably underdiagnosed intraspinal tumors is given.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenocortical Adenoma / pathology. Spinal Cord Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2005 Sep;60(9):953-9 [16124976.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):260-5 [12053045.001]
  • [Cites] Spinal Cord. 2007 Feb;45(2):183-6 [16505829.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):310-2 [11302638.001]
  • [Cites] J Pediatr Surg. 1980 Jun;15(3):289-92 [6103925.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Histopathology. 1997 Aug;31(2):167-73 [9279569.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):375-82 [9130983.001]
  • [Cites] J Med Case Rep. 2008 Jul 13;2:228 [18620603.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Histopathology. 1986 Mar;10(3):311-9 [2422107.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Jul-Aug;25(4):191-7 [17162526.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):756-9 [10981764.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4283-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative lesion sequencing provides insights into tumor evolution.
  • We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common.
  • When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize;.
  • (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells.
  • These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] World J Surg. 2004 Mar;28(3):263-70 [14961200.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Humangenetik. 1972;16(1):87-110 [4647448.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1650-5 [6299526.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6109-14 [3167857.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):968-71 [2159442.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):60-6 [1998868.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):435-41 [7640229.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cytometry. 1997 Nov 1;29(3):273-8 [9389445.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):213-22 [9748584.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):803-11 [10091757.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1963 Oct;90:673-87 [14068399.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8111-7 [16166284.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):610-4 [16582617.001]
  • [Cites] Cancer Sci. 2006 May;97(5):362-7 [16630132.001]
  • [Cites] Nat Methods. 2006 Jul;3(7):551-9 [16791214.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227 [17178965.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Nat Protoc. 2006;1(2):859-69 [17406318.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 [12857956.001]
  • (PMID = 18337506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R01 CA127306; United States / NCI NIH HHS / CA / CA121113; United States / NIGMS NIH HHS / GM / GM078986; United States / NCI NIH HHS / CA / CA127306; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIGMS NIH HHS / GM / R01 GM078986; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R01 CA120237; United States / NCI NIH HHS / CA / R01 CA121113; United States / NIGMS NIH HHS / GM / GM078986-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043703; United States / NCI NIH HHS / CA / CA120237; United States / NCI NIH HHS / CA / U54 CA116867; United States / NIGMS NIH HHS / GM / R01 GM078986-02; United States / NCI NIH HHS / CA / CA116867; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA105090
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2393770
  •  go-up   go-down


37. Obulareddy SJ, Xin J, Truskinovsky AM, Anderson JK, Franklin MJ, Dudek AZ: Metanephric adenoma of the kidney: an unusual diagnostic challenge. Rare Tumors; 2010;2(2):e38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although metanephric adenoma (MA) is a rare, benign neoplasm of epithelial cells, it is often difficult to distinguish this entity from other malignant neoplasms preoperatively.
  • We report a case of a large renal mass for which preoperative diagnosis was indeterminate, with the differential diagnosis including Wilm's tumor, MA, and papillary renal cell carcinoma (PRCC).
  • Accurate postoperative differentiation of MA from PRCC is critical because adjuvant therapy is considered after surgical resection of PRCC tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139840.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994510
  • [Keywords] NOTNLM ; Wilm’s tumor / differential diagnosis. / metanephric adenoma / papillary renal cell carcinoma
  •  go-up   go-down


38. Redjimi N, Gaudin F, Touboul C, Emilie D, Pallardy M, Biola-Vidamment A, Fernandez H, Prévot S, Balabanian K, Machelon V: Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer. Mol Cancer; 2009;8:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer.
  • BACKGROUND: Little is known about the molecules that contribute to tumor progression of epithelial ovarian cancer (EOC), currently a leading cause of mortality from gynecological malignancies.
  • The objectives of the current study were to examine the expression of GILZ in EOC and its effect on tumor cell proliferation.
  • RESULTS: GILZ expression was measured by immunohistochemical staining in tissue sections from 3 normal ovaries, 7 benign EOC and 50 invasive EOC.
  • GILZ was not detected on the surface epithelium of normal ovaries and benign tumors.
  • In contrast, it was expressed in the cytoplasm of tumor cells in 80% EOC specimens.
  • They were also higher in tumor cells containing large amounts of phosphorylated protein kinase B (p-AKT) (unpaired t test, P < 0.0001).
  • To assess the effect of GILZ on proliferation and AKT activation, we used the BG-1 cell line derived from ovarian tumor cells as a cellular model.
  • [MeSH-major] Epithelial Cells / pathology. Ovarian Neoplasms / pathology. Transcription Factors / metabolism


39. Singhal V, Sharma SC, Anil J, Sachan PK, Harsh M, Singhal S, Raghuvanshi S: Giant benign nodular hidradenoma of the shoulder: A rare tumor in orthopedic practice. Int J Shoulder Surg; 2010 Oct;4(4):93-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant benign nodular hidradenoma of the shoulder: A rare tumor in orthopedic practice.
  • A clear cell hidradenoma is a rare dermal tumor, which is believed to originate from the apical portion of the sweat glands.
  • This lesion has not been reported to be large enough to impinge a joint range of motion.
  • We present a giant benign nodular hidradenoma presenting as painful restriction of the right shoulder joint in a 35-year-old male.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Korean J Radiol. 2010 Jul-Aug;11(4):490-2 [20592936.001]
  • [Cites] AJR Am J Roentgenol. 1990 Dec;155(6):1251-5 [2122675.001]
  • [Cites] J Bone Joint Surg Am. 1982 Jun;64(5):780-2 [6282887.001]
  • (PMID = 21655004.001).
  • [ISSN] 0973-6042
  • [Journal-full-title] International journal of shoulder surgery
  • [ISO-abbreviation] Int J Shoulder Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  • [Other-IDs] NLM/ PMC3100814
  • [Keywords] NOTNLM ; Axillary mass / nodular hidradenoma
  •  go-up   go-down


40. Panagiotou M, Panagopoulos ND, Ravazoula P, Kaklamanis L, Koletsis EN: Large asymptomatic left atrial myxoma with ossification: case report. J Cardiothorac Surg; 2008;3:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large asymptomatic left atrial myxoma with ossification: case report.
  • BACKGROUND: Atrial myxomas are the most common primary cardiac tumors.
  • They are usually small or moderate in size by the time of the diagnosis, exhibiting non specific cardiac or systemic symptoms, and are most frequently soft and friable without microscopic signs of ossification.
  • CASE PRESENTATION: An asymptomatic 58-year-old male with a giant left atrial tumor, was transferred to our Unit for surgical treatment.
  • The tumor was an incidental finding during a work-up for hemoptysis due to bronchectasis.
  • The coronary angiogram showed tumor vessels originating from the RCA.
  • The tumor macroscopically did not resemble a myxoma, considering its dimensions (12 x 10 cm) and its solid substance.
  • The pathology study revealed a benign myxoma with excessive osteoid (mature bone) content.
  • CONCLUSION: We consider our case as extremely rare because of the asymptomatic course despite the large size of the tumor, the blood supply from the right coronary artery and the bone formation.
  • [MeSH-major] Calcinosis / complications. Cardiomyopathies / complications. Heart Neoplasms / complications
  • [MeSH-minor] Cardiac Surgical Procedures / methods. Coronary Angiography. Diagnosis, Differential. Heart Atria. Humans. Male. Middle Aged. Myxoma. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Dec 14;333(24):1610-7 [7477198.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1996 Sep;44(9):1796-9 [8911059.001]
  • [Cites] Am J Cardiol. 1999 Jun 1;83(11):1579-82, A8 [10363879.001]
  • [Cites] Vet Pathol. 2000 Sep;37(5):460-2 [11055869.001]
  • [Cites] Heart. 2001 Aug;86(2):206 [11454844.001]
  • [Cites] Kyobu Geka. 2002 May;55(5):376-8 [11995318.001]
  • [Cites] Int J Cardiol. 2002 Jul;84(1):69-75 [12104067.001]
  • [Cites] Z Kardiol. 2004 Jan;93(1):69-71 [14740244.001]
  • [Cites] J Interv Cardiol. 1993 Jun;6(2):125-9 [10150999.001]
  • (PMID = 18445263.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2383893
  •  go-up   go-down


41. Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Königsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol; 2008 Apr;134(4):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel.
  • PURPOSE: Pheochromocytoma (PCC) is a usually benign tumor originated in the majority of patients from the adrenal medulla.
  • Since microsatellite markers used for MSI detection have only been recommended for colorectal carcinoma (CRC), we established an extended marker set for MSI detection in PCC.
  • Our marker set comprised the reference panel for CRC and six additional markers, which have already been described to detect MSI in tumors other than CRC.
  • Moreover, 23 endocrine tumors with gastrointestinal origin were examined in order to test the applicability of this marker panel.
  • Among the 23 patients with endocrine tumors, only three (one pancreatic endocrine tumor, one duodenal neuro-endocrine tumor, one hepatic metastasis of a primary tumor with unknown origin) demonstrated MSI.
  • [MeSH-major] Endocrine Gland Neoplasms / genetics. Loss of Heterozygosity. Microsatellite Instability. Microsatellite Repeats. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms / genetics. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 1:255-65 [12616616.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):353-60 [11433399.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3444-9 [11705861.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1564-7 [15619218.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):93-8 [17143284.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1114-5 [17021141.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):895-903 [9536095.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):359-65 [15796198.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2536-40 [12171881.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):625-31 [16557375.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):10-1 [17192781.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1240-6 [16715450.001]
  • [Cites] Exp Mol Med. 2004 Apr 30;36(2):122-9 [15150440.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):135-42 [10845276.001]
  • [Cites] Surgery. 2003 Dec;134(6):902-8; discussion 909 [14668721.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):607-18 [17055172.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):145-52 [16724208.001]
  • (PMID = 17828419.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. de Bruin AF, Verhoef C, den Bakker MA, van Geel A: Glomus tumor of the mesentery with atypical features: a case report. Int J Surg Pathol; 2008 Oct;16(4):440-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomus tumor of the mesentery with atypical features: a case report.
  • Glomus tumors usually occur in the acral soft tissue and rarely in visceral locations, such as the stomach, intestines, mediastinum, lung, pancreas, bladder, and vagina.
  • The authors present a 74-year-old woman with an exceptionally large glomus tumor of the mesentrium with malignant features.
  • Previously reported cases of intraabdominal glomus tumor in the abdominal cavity exhibited benign behavior and few cases with metastatic disease.
  • Criteria for malignancy in acral glomus tumors, such as unusually large size, infiltrative growth, necrosis, nuclear atypia, and mitotic activity, seem not to translate to abdominal glomus tumors.
  • As very few intraabdominal glomus are described, the malignant potential of these tumors stays uncertain for longer period.
  • [MeSH-major] Glomus Tumor / pathology. Mesentery / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492684.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Cutress ML, Ratan HL, Williams ST, O'Brien MF: Update on the management of T1 renal cortical tumours. BJU Int; 2010 Oct;106(8):1130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A large number of such tumours are benign and might therefore be over-treated with radical nephrectomy.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Catheter Ablation / methods. Cryotherapy / methods. Kidney Cortex. Kidney Neoplasms / therapy. Nephrectomy / methods
  • [MeSH-minor] Disease Progression. Humans. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20738293.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


45. Jurkiewicz BD: Rare case of pyogenic granuloma of the tongue in an 8-week-old infant. Eur Arch Otorhinolaryngol; 2005 Jun;262(6):453-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a large pyogenic granuloma of the tongue causing swallowing difficulties in an 8-week-old infant.
  • It was an easily bleeding pedunculated tumor measuring 3 x 2.5 cm.
  • The etiology of the tumor is unknown; it can arise in sites of previous injury, chronic irritation and infection.
  • The course of the disease is benign and painless, though it can be recurrent.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Tongue / surgery. Tongue Diseases / diagnosis

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Tongue Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pediatr Otorhinolaryngol. 2001 May 11;58(3):239-41 [11335013.001]
  • [Cites] Saudi Med J. 2001 Dec;22(12):1130-2 [11802191.001]
  • [Cites] Am J Surg. 1965 Apr;109:430-1 [14270435.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):521-3 [11442586.001]
  • [Cites] Acta Chir Plast. 2003;45(2):52-4 [12921260.001]
  • [Cites] Arch Pediatr Adolesc Med. 2001 Sep;155(9):1065-6 [11529811.001]
  • [Cites] Dent Update. 2002 Nov;29(9):462-3 [12494563.001]
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):445-9 [10752998.001]
  • [Cites] Ann Dermatol Venereol. 1996;123(9):552-4 [9615106.001]
  • (PMID = 15549337.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Führer D, Schmid KW: [Benign thyroid nodule or thyroid cancer?]. Internist (Berl); 2010 May;51(5):611-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign thyroid nodule or thyroid cancer?].
  • Differential diagnosis of thyroid nodules is directed at exclusion of thyroid autonomy and thyroid cancer.
  • In addition, large nodules/nodular goiters may cause oesophageal and/or tracheal compression.
  • Besides the patient's history and clinical examination, laboratory investigations (TSH-level, calcitonin screening), functional (scintiscan) and morphological imaging (ultrasound, in rare cases also CT without contrast media and MRI), as well as fine needle aspiration biopsy are useful tools in the differential diagnosis.
  • In the past years, major advances have been made in the understanding of the molecular pathogenesis of thyroid tumors.
  • This has led to the possibility of a molecular classification of thyroid tumors and may have prognostic as well as therapeutic impact.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / blood. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2006 Jan-Feb;12(1):63-102 [16596732.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1748-51 [19276237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nuklearmedizin. 2003 Oct;42(5):181-9 [14571314.001]
  • [Cites] Histopathology. 2010 Apr;56(5):632-40 [20459574.001]
  • [Cites] Endocr Rev. 2007 May;28(3):322-38 [17353294.001]
  • [Cites] Thyroid. 2003 Aug;13(8):803-10 [14558922.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8 [16478817.001]
  • [Cites] Endocr Rev. 2005 Jun;26(4):504-24 [15615818.001]
  • [Cites] Dtsch Med Wochenschr. 2005 Aug 5;130(31-32):1831-6 [16052449.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):957-77 [18045949.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):475-81 [19370508.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Virchows Arch. 2009 Jul;455(1):21-33 [19543912.001]
  • [Cites] Pathologe. 2003 Sep;24(5):357-72 [12961024.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):903-11 [11981026.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Aug;94(8):2970-4 [19491231.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):376-82 [20029416.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):482-7 [19370505.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Feb;117(2):145-53 [2837884.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Thyroid. 2009 Jun;19(6):565-612 [19469690.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):713-20 [17893690.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1390-3 [18198227.001]
  • [Cites] Nuklearmedizin. 2003 Jun;42(3):120-2 [12802476.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1600-8 [18270258.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):385-93 [16506015.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Histopathology. 2008 Apr;52(5):623-30 [18370959.001]
  • (PMID = 20405098.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


47. Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, Knuechel R, Blaszyk H, Hartmann A, Wild PJ: Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy. Int J Oncol; 2007 Oct;31(4):793-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
  • The aim of this study was to investigate STK15 amplification in histologically benign urothelium and invasive tumor tissue of urothelial bladder cancer patients in relation to clinicopathologic and molecular characteristics, and to analyze a hypothesized association between the STK15 single nucleotide polymorphism at site T91A (Phe31Ile) and STK15 gene amplification.
  • A tissue microarray (TMA) was constructed and contained formalin-fixed paraffin-embedded tumor tissue and matching histologically benign urothelium of 44 patients who underwent cystectomy for invasive urothelial carcinoma.
  • Low level STK15 amplification was found in 2 of 36 analyzable histologically benign urothelium specimens (5.6%) and in 64% (28/44) of urothelial bladder cancers, whereas 36% (16/44) of cancer lesions showed high level of STK15 amplification.
  • In histologically benign urothelium of bladder cancer patients, low level STK15 amplification was associated with shorter recurrence-free and tumor-specific survival.
  • Applying STK15 FISH to benign urothelium of bladder cancer patients may help to identify patients at increased risk for adverse clinical outcome.
  • A large randomized prospective study comparing early versus delayed cystectomy in patients with pT1 bladder cancer is currently conducted to validate our findings.
  • [MeSH-major] Cystectomy. Protein-Serine-Threonine Kinases / genetics. Urinary Bladder Neoplasms / genetics. Urothelium / pathology
  • [MeSH-minor] Aged. Aurora Kinase A. Aurora Kinases. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Case-Control Studies. Chromosome Aberrations. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / surgery. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Precancerous Conditions / pathology. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786310.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


48. Bhattacharjee N, Li N, Keenan TM, Folch A: A neuron-benign microfluidic gradient generator for studying the response of mammalian neurons towards axon guidance factors. Integr Biol (Camb); 2010 Nov;2(11-12):669-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A neuron-benign microfluidic gradient generator for studying the response of mammalian neurons towards axon guidance factors.
  • In this paper, we describe axonal responses of mouse cortical neurons in a "neuron-benign" gradient-generator device based on an open chamber that can establish highly stable gradients of diffusible molecules for at least 6 h with negligible shear stress, and also allows the neurons to thrive for at least 2 weeks.
  • The gradient stability and uniformity over the cell culture surface achieved by the device, together with our software platform for acquiring, post-processing and quantitatively analyzing the large number of images allowed us to extract valuable information even from small datasets.
  • We infer from our studies that a large majority (∼73%) of the neurons that extend axons during the gradient application grow towards the netrin source, and our data analysis also indicates that netrin acts as a growth factor for this same population of neurons.
  • [MeSH-minor] Animals. Axons / drug effects. Axons / physiology. Cell Culture Techniques. Cell Tracking. Equipment Design. Female. Mice. Nerve Growth Factors / pharmacology. Neurogenesis. Pregnancy. Signal Transduction. Tumor Suppressor Proteins / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 1996 Aug;17(2):203-15 [8780645.001]
  • [Cites] J Neurosci Res. 1995 Dec;42(5):674-83 [8600300.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Mol Cell Neurosci. 1997;8(6):417-29 [9143559.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):275-9 [9230436.001]
  • [Cites] Neuron. 1997 Sep;19(3):575-89 [9331350.001]
  • [Cites] Neuron. 1997 Dec;19(6):1211-24 [9427245.001]
  • [Cites] Development. 1997 Dec;124(24):5063-74 [9362464.001]
  • [Cites] Cell. 1999 Jun 25;97(7):821-4 [10399909.001]
  • [Cites] Curr Opin Neurobiol. 1999 Oct;9(5):603-15 [10508749.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):833-9 [15679351.001]
  • [Cites] Lab Chip. 2005 Apr;5(4):401-6 [15791337.001]
  • [Cites] Lab Chip. 2005 Jun;5(6):611-8 [15915253.001]
  • [Cites] Exp Cell Res. 2005 Dec 10;311(2):307-16 [16263111.001]
  • [Cites] Nat Neurosci. 2006 Apr;9(4):511-8 [16520734.001]
  • [Cites] Dev Biol. 2006 Apr 1;292(1):13-24 [16476423.001]
  • [Cites] Biomed Microdevices. 2006 Jun;8(2):109-18 [16688570.001]
  • [Cites] Development. 2006 Jul;133(13):2487-95 [16763203.001]
  • [Cites] Lab Chip. 2007 Jun;7(6):763-9 [17538719.001]
  • [Cites] Langmuir. 2007 Oct 23;23(22):10910-2 [17910490.001]
  • [Cites] Lab Chip. 2008 Jan;8(1):34-57 [18094760.001]
  • [Cites] Lab Chip. 2008 Feb;8(2):227-37 [18231660.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):698-706 [18469807.001]
  • [Cites] Lab Chip. 2008 Aug;8(8):1292-9 [18651071.001]
  • [Cites] Lab Chip. 2008 Sep;8(9):1468-77 [18818801.001]
  • [Cites] Lab Chip. 2008 Sep;8(9):1507-15 [18818806.001]
  • [Cites] Lab Chip. 2010 Jan 7;10(1):116-22 [20024059.001]
  • [Cites] Cell. 2010 May 14;141(4):632-44 [20434207.001]
  • [Cites] J Comp Neurol. 2000 Jan 10;416(2):201-12 [10581466.001]
  • [Cites] Int J Dev Neurosci. 2000 Nov;18(7):643-51 [10978842.001]
  • [Cites] Nat Neurosci. 2001 Nov;4 Suppl:1169-76 [11687826.001]
  • [Cites] Neuron. 2001 Nov 20;32(4):605-17 [11719202.001]
  • [Cites] Prog Neurobiol. 2001 Dec;65(6):593-608 [11728645.001]
  • [Cites] J Neurobiol. 2002 Apr;51(1):9-23 [11920724.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86 [12094214.001]
  • [Cites] Nat Biotechnol. 2002 Aug;20(8):826-30 [12091913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12542-7 [12237407.001]
  • [Cites] Lab Chip. 2004 Oct;4(5):420-4 [15472724.001]
  • [Cites] Nature. 1988 Dec 22-29;336(6201):775-8 [3205306.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • (PMID = 20957287.001).
  • [ISSN] 1757-9708
  • [Journal-full-title] Integrative biology : quantitative biosciences from nano to macro
  • [ISO-abbreviation] Integr Biol (Camb)
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064387
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1
  • [Other-IDs] NLM/ NIHMS513943; NLM/ PMC3786697
  •  go-up   go-down


49. Thyavihally YB, Tongaonkar HB, Desai SB: Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report. Int Semin Surg Oncol; 2005 Sep 9;2:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed epithelial stromal tumor of the renal pelvis with exophytic growth: case report.
  • BACKGROUND: Mixed epithelial and stromal tumor (MEST) is a distinctive benign composite neoplasm of the kidney predominantly seen in females mostly in the perimenopausal period.
  • Although these tumors are known to arise from renal pelvis, our case was distinct in that it had no intrapelvic component growing in exophytic fashion.
  • Microscopically, the tumor was composed of large collagenized areas containing bundles of spindle cells and several 'microcysts' lined by cuboidal epithelium suggestive of a benign mixed epithelial stromal tumor.
  • DISCUSSION: Mixed epithelial tumors usually present in perimenopausal women as a partially cystic mass.
  • Tumors are composed of irregular mixtures of cystic and solid areas, glands with variable complexity and distribution and the stromal component is characterized by a spindle cell proliferation.
  • Commonly, it arises from the renal parenchyma and pelvis and nephrectomy is advocated to manage these tumors.
  • CONCLUSION: MEST is a distinctive benign tumor of the kidney that should be distinguished from other renal neoplasms.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2004 Dec;5(12):747-9 [15581546.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • [Cites] Hum Pathol. 2001 May;32(5):513-20 [11381370.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):2-20 [9503503.001]
  • [Cites] Hinyokika Kiyo. 2004 Jan;50(1):49-52 [15032017.001]
  • [Cites] Pathologe. 2004 Sep;25(5):356-61 [15127227.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):223-33 [12826829.001]
  • (PMID = 16150156.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1215508
  •  go-up   go-down


50. Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, Sauter G, Haese A: Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol; 2010 Dec;28(6):687-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Angiogenesis is an important part in tumor progression and intratumoral microvessel density (MVD) has proven a prognostic factor in several solid tumors.
  • We evaluated the prognostic potential of MVD in a large, homogeneous cohort of prostate cancers and its correlation with other pathologic parameters.
  • RESULTS: MVD was higher in TMA spots containing cancer as compared to benign tissue (P < 0.001).
  • Furthermore, a higher MVD correlated with tumor location in the peripheral zone (P = 0.01).
  • CONCLUSIONS: MVD in prostate cancer is closely related to other factors contributing to tumor aggressiveness.
  • [MeSH-major] Disease Progression. Microvessels / pathology. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / blood supply. Prostatic Neoplasms / diagnosis


51. Zografos GN, Vasiliadis G, Farfaras AN, Aggeli C, Digalakis M: Laparoscopic surgery for malignant adrenal tumors. JSLS; 2009 Apr-Jun;13(2):196-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for malignant adrenal tumors.
  • Advances in imaging have improved early detection of primary and metastatic adrenal tumors.
  • The laparoscopic approach, the gold standard for benign adrenal diseases, is controversial for malignant adrenal tumors.
  • A review of the literature demonstrates the safety and efficacy of laparoscopic adrenalectomy for solitary adrenal tumors.
  • In primary adrenal malignancies, the laparoscopic approach should be considered cautiously, only when it can achieve complete tumor resection with an intact adrenal capsule.
  • Conversion to an open procedure should be an early decision, prior to tumor morcellation or fracture of the tumor capsule.
  • Patients who have local invasion, tumors that are too large, or require organ resection require an open procedure.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Hormones (Athens). 2006 Jan-Mar;5(1):52-6 [16728385.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):128-31 [16847903.001]
  • [Cites] Clin Nucl Med. 2006 Dec;31(12):822-5 [17117086.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156(4):483-7 [17389464.001]
  • [Cites] J Endocrinol Invest. 2007 Mar;30(3):200-4 [17505152.001]
  • [Cites] Surg Endosc. 2007 Aug;21(8):1373-6 [17356945.001]
  • [Cites] JSLS. 2007 Apr-Jun;11(2):261-5 [17761094.001]
  • [Cites] JSLS. 2007 Oct-Dec;11(4):487-92 [18237516.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2008 Feb;18(1):42-6 [18266573.001]
  • [Cites] Surg Clin North Am. 2000 Oct;80(5):1427-41 [11059712.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Surgery. 2001 Dec;130(6):1072-7 [11742341.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2001 Dec;11(6):409-13 [11814133.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):948-51; discussion 952-3 [12146996.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Ann Chir. 2002 Sep;127(7):512-9 [12404845.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:132s-138s [12487269.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Apr;13(2):106-10 [12709616.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):105-23 [12946482.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1191-6 [14654476.001]
  • [Cites] Minerva Chir. 2004 Feb;59(1):1-5 [15111826.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):755-74 [15145233.001]
  • [Cites] Am J Surg. 2004 Jun;187(6):705-12 [15191862.001]
  • [Cites] Am Surg. 2004 Aug;70(8):668-74 [15328798.001]
  • [Cites] N Engl J Med. 1984 Nov 15;311(20):1298-303 [6149463.001]
  • [Cites] J Surg Oncol. 1992 Aug;50(4):258-62 [1640712.001]
  • [Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):631-42 [1479146.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):643-9 [1479147.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):15-9 [8349158.001]
  • [Cites] Intern Med. 1993 Oct;32(10):789-94 [8012074.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):149-54 [7898109.001]
  • [Cites] Eur J Nucl Med. 1995 Apr;22(4):315-21 [7607261.001]
  • [Cites] Am J Hypertens. 1997 Apr;10(4 Pt 1):479-81 [9128218.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1317-24 [9141510.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):914-9 [9267279.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):238-46; discussion 246-7 [9339930.001]
  • [Cites] J Urol. 1997 Dec;158(6):2227 [9366350.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):389-94 [9445197.001]
  • [Cites] Urology. 1998 Jun;51(6):920-5 [9609627.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):765-89 [9735133.001]
  • [Cites] Cytokine. 1998 Sep;10(9):720-8 [9770334.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1721-4 [9893659.001]
  • [Cites] Semin Surg Oncol. 1999 Jun;16(4):293-306 [10332775.001]
  • [Cites] BJU Int. 2004 Nov;94(7):1026-9 [15541121.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):718-26 [15581542.001]
  • [Cites] J Urol. 2005 Feb;173(2):519-25 [15643237.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1176-9 [15490056.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Mar;5(2):139-48 [15810878.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):405-11 [15820450.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 May;27(5):753-6 [15848309.001]
  • [Cites] Horm Metab Res. 2005 Dec;37(12):717-21 [16372223.001]
  • [Cites] World J Surg. 2006 May;30(5):893-8 [16680605.001]
  • [Cites] Semin Nucl Med. 2006 Jul;36(3):228-47 [16762613.001]
  • (PMID = 19660215.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  • [Other-IDs] NLM/ PMC3015945
  •  go-up   go-down


52. Weng J, Wang J, Hu X, Wang F, Ittmann M, Liu M: PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int J Cancer; 2006 Mar 15;118(6):1471-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The G-protein coupled receptors (GPCRs) recognize a large variety of extracellular molecules (such as hormones, neurotransmitters, growth and developmental factors) and several sensory messages (such as light, odors and pain).
  • Although PSGR2 shares sequence homology with human olfactory G-protein coupled receptors, the expression of PSGR2 is highly restricted to human prostate tissue, and no expression was detected in 22 normal and 10 tumor tissues examined using Northern blot and PCR analysis.
  • We demonstrated that PSGR2 expression increased significantly in human high grade prostate intraepithelial neoplasia (PIN) and prostate cancers (approximately 10-fold) as compared to normal and BPH (benign prostatic hyperplasia) tissues (p < 0.001), suggesting PSGR2 may play an important role in human prostate cancer development and progression.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. Prostatic Neoplasms / genetics. Receptors, G-Protein-Coupled / genetics
  • [MeSH-minor] Amino Acid Sequence. Analysis of Variance. Biomarkers, Tumor / genetics. Blotting, Northern. Chromosome Mapping. Chromosomes, Human, Pair 11. Female. Gene Expression Profiling. Humans. In Situ Hybridization. Male. Molecular Sequence Data. Phylogeny. Prostate / metabolism. Prostate / pathology. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Intraepithelial Neoplasia / pathology. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction. Sequence Homology, Amino Acid

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206286.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R21 CA104318; United States / NCI NIH HHS / CA / P50CA058204
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / OR51E1 protein, human; 0 / Receptors, G-Protein-Coupled
  •  go-up   go-down


53. Noudel R, Chauvet E, Cahn V, Mérol JC, Chays A, Rousseaux P: Transcranial resection of a large sinonasal juvenile psammomatoid ossifying fibroma. Childs Nerv Syst; 2009 Sep;25(9):1115-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcranial resection of a large sinonasal juvenile psammomatoid ossifying fibroma.
  • INTRODUCTION: Juvenile psammomatoid ossifying fibroma (JPOF) is a benign but potentially locally aggressive fibroosseous lesion predominantly arising in the paranasal sinuses in children and young adults.
  • In such cases, tumor resection may often require the combination of neurosurgical and facial approaches.
  • Histological diagnosis remains a challenge because the lesion can be easily mistaken for another fibroosseous lesion or for a meningioma.
  • Despite the tumor had eroded through nasal septum, medial orbit wall, and right maxilla, it could be entirely removed performing an extended frontobasal approach via a bifrontoorbital craniotomy, obviating the need for a transfacial approach.
  • [MeSH-major] Fibroma, Ossifying / surgery. Skull Neoplasms / surgery
  • [MeSH-minor] Child. Craniotomy / methods. Diagnosis, Differential. Humans. Male. Prognosis. Skull / diagnostic imaging. Skull / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Oct 1;76(7):1155-65 [8630892.001]
  • [Cites] J Oral Pathol Med. 2000 Jan;29(1):13-8 [10678711.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 May;101(5):614-9 [16632273.001]
  • [Cites] Head Neck. 1998 Mar;20(2):97-105 [9484939.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2000 Aug 31;54(2-3):159-62 [10967388.001]
  • [Cites] Pediatr Neurosurg. 2003 Nov;39(5):270-4 [14512692.001]
  • [Cites] Semin Diagn Pathol. 1996 May;13(2):104-12 [8734416.001]
  • [Cites] Acta Otolaryngol Suppl. 1991;488:1-40 [1843064.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Mar;93(3):296-304 [11925539.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1151-4 [16028779.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2006 Feb;70(2):193-9 [16321450.001]
  • [Cites] Am J Rhinol. 2001 Jan-Feb;15(1):27-30 [11258651.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):126-43 [11345237.001]
  • [Cites] Am J Otolaryngol. 2005 Jan-Feb;26(1):54-6 [15635583.001]
  • [Cites] J Oral Pathol Med. 1994 Oct;23(9):385-8 [7823298.001]
  • [Cites] J Craniomaxillofac Surg. 1987 Jun;15(3):154-67 [3475289.001]
  • [Cites] Otolaryngol Head Neck Surg. 1991 Jun;104(6):803-8 [1908971.001]
  • [Cites] Skull Base Surg. 1999;9(2):95-100 [17171124.001]
  • [Cites] J Craniomaxillofac Surg. 1998 Oct;26(5):314-7 [9819682.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan-Feb;12 (1):25-30 [1899514.001]
  • [Cites] Ear Nose Throat J. 2007 Jul;86(7):400-1 [17702320.001]
  • [Cites] J Neurosurg. 1992 Feb;76(2):198-206 [1730948.001]
  • (PMID = 19308423.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Hirn M, de Silva U, Sidharthan S, Grimer RJ, Abudu A, Tillman RM, Carter SR: Bone defects following curettage do not necessarily need augmentation. Acta Orthop; 2009 Feb;80(1):4-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The natural pattern of bone healing in large bony defects following curettage alone as treatment of benign bone tumors around the knee is not well reported.
  • PATIENTS AND METHODS: 146 patients with over 18 months of follow-up who underwent curettage without bone substitute filling or bone grafting for a benign tumor in the distal femur or upper tibia were included.
  • The risk of subsequent fracture or the late development of osteoarthritis was strongly related to the size of the cyst at diagnosis, with cysts of > 60 cm(3) (about 5 cm in diameter) having a much higher incidence of complications.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Substitutes. Bone Transplantation

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Orthop B. 2006 May;15(3):155-67 [16601582.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):275-90 [7105588.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):495-8 [16896875.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):505-9 [16969579.001]
  • [Cites] J Surg Oncol. 2007 Sep 1;96(3):230-4 [17443729.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):9-13 [19234882.001]
  • [Cites] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):200-2 [11289759.001]
  • [Cites] J Bone Joint Surg Am. 2002 Mar;84-A(3):454-64 [11886919.001]
  • [Cites] Clin Orthop Relat Res. 2002 Feb;(395):44-52 [11937865.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):248-58 [11953616.001]
  • [Cites] J Hand Surg Br. 2002 Dec;27(6):538-41 [12475511.001]
  • [Cites] J Bone Joint Surg Br. 2004 Mar;86(2):212-6 [15046435.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jul;(424):221-6 [15241169.001]
  • [Cites] J Biomech. 2006;39(8):1507-16 [15972212.001]
  • [Cites] Clin Orthop Relat Res. 1984 May;(185):306-10 [6705395.001]
  • [Cites] Acta Orthop Scand. 1984 Dec;55(6):597-600 [6524324.001]
  • [Cites] Int Orthop. 1985;8(4):287-94 [4018963.001]
  • [Cites] Ital J Orthop Traumatol. 1985 Sep;11(3):381-8 [4086284.001]
  • [Cites] Arch Orthop Trauma Surg. 1993;112(4):167-70 [8357691.001]
  • [Cites] J Bone Joint Surg Am. 1994 Dec;76(12):1827-33 [7989388.001]
  • [Cites] J Bone Joint Surg Am. 1995 Nov;77(11):1742-54 [7593087.001]
  • [Cites] Acta Orthop Scand. 1996 Dec;67(6):536-40 [9065062.001]
  • [Cites] J Biomed Mater Res. 1997 Apr;35(1):9-17 [9104694.001]
  • [Cites] Plast Reconstr Surg. 1998 Mar;101(3):660-72 [9500382.001]
  • [Cites] Acta Orthop Scand. 1998 Dec;69(6):557-8 [9930096.001]
  • [Cites] J Bone Joint Surg Am. 1999 Jun;81(6):811-20 [10391546.001]
  • [Cites] Clin Orthop Relat Res. 2005 Jun;(435):211-8 [15930941.001]
  • [Cites] J Bone Joint Surg Br. 2006 Apr;88(4):531-5 [16567792.001]
  • [CommentIn] Acta Orthop. 2009 Feb;80(1):2-3 [19297784.001]
  • (PMID = 19234881.001).
  • [ISSN] 1745-3682
  • [Journal-full-title] Acta orthopaedica
  • [ISO-abbreviation] Acta Orthop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Bone Substitutes
  • [Other-IDs] NLM/ PMC2823228
  •  go-up   go-down


55. Tanigawa N, Nomura E, Lee SW, Kaminishi M, Sugiyama M, Aikou T, Kitajima M, Society for the Study of Postoperative Morbidity after Gastrectomy: Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. World J Surg; 2010 Jul;34(7):1540-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Carcinoma of the gastric remnant after partial gastrectomy for benign disease or cancer is unusual but an important cancer model.
  • METHODS: In the questionnaire survey of November 2008, gastric stump carcinoma was defined as an adenocarcinoma of the stomach occurring 10 years or more after Billroth I or Billroth II gastrectomy for benign condition or cancer disease.
  • Items for the survey included gender, age, methods of reconstruction in an original gastrectomy, original diseases, time interval between original gastrectomy and first detection of stump carcinomas, locations of stump carcinomas, tumor histology, tumor depth, and extent of lymph node metastasis.
  • The Billroth II group has a significantly higher number of original benign lesions than the Billroth I group (P < 0.001).
  • (3) Tumor histology of 72.4% of 304 stump carcinomas at an early stage was intestinal type adenocarcinoma, i.e., well or moderately differentiated adenocarcinoma, whereas it decreased to 42.2% at the locally advanced stage of 521 stump carcinomas (P = 0.0015), suggesting that stump carcinoma mostly may develop from intestinal type and change to diffuse type during the evolution to advanced stage cancers.
  • CONCLUSIONS: This large series of surveys suggest that there are two distinct biological plausibilities in the development of gastric stump carcinoma:.
  • (1) it develops in a shorter time interval of 10 years or less since the original gastrectomy, may come from a higher risk of gastric mucosa after gastrectomy for cancer diseases that highly predisposes to cancer, and (2) it develops during a longer time interval of 20 years or more, may come from gastrectomy-relating mechanisms after gastrectomy for original benign diseases.
  • [MeSH-major] Adenocarcinoma / epidemiology. Gastric Stump. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1971 Apr;102(4):260-5 [4928618.001]
  • [Cites] Cancer. 1972 Jan;29(1):205-9 [5007382.001]
  • [Cites] Am J Surg. 1976 Jul;132(1):26-31 [952334.001]
  • [Cites] Lancet. 1976 Nov 13;2(7994):1037-9 [62896.001]
  • [Cites] Lancet. 1980 Apr 5;1(8171):727-9 [6103154.001]
  • [Cites] World J Surg. 1981 Jul;5(4):595-605 [7324494.001]
  • [Cites] N Engl J Med. 1982 Aug 26;307(9):519-22 [7099223.001]
  • [Cites] Br J Surg. 1983 Jun;70(6):322-5 [6860906.001]
  • [Cites] Br J Surg. 1983 Sep;70(9):552-4 [6616162.001]
  • [Cites] N Engl J Med. 1983 Nov 17;309(20):1210-3 [6633569.001]
  • [Cites] Cancer Res. 1984 May;44(5):2208-12 [6713408.001]
  • [Cites] J Natl Cancer Inst. 1984 Jun;72(6):1431-5 [6587160.001]
  • [Cites] Clin Gastroenterol. 1984 May;13(2):569-600 [6378447.001]
  • [Cites] J Clin Pathol. 1984 Jul;37(7):748-54 [6747012.001]
  • [Cites] Lancet. 1986 Apr 26;1(8487):929-31 [2871238.001]
  • [Cites] Lancet. 1986 Aug 30;2(8505):502-5 [2875248.001]
  • [Cites] Jpn J Cancer Res. 1987 Apr;78(4):337-48 [3108214.001]
  • [Cites] N Engl J Med. 1988 Jul 28;319(4):195-200 [3393171.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):365-7 [3417364.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6486-9 [2145061.001]
  • [Cites] Langenbecks Arch Chir. 1991;376(1):16-22 [2034000.001]
  • [Cites] Gut. 1991 Jul;32(7):740-4 [1855679.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Carcinogenesis. 1992 Dec;13(12):2313-6 [1473239.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 18;85(16):1303-10 [8340942.001]
  • [Cites] Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:3-11 [10209681.001]
  • [Cites] Ann Surg. 1956 Feb;143(2):173-9 [13292871.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2002;5(1):23-8 [12021856.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul;20 Suppl 1:85-9 [15298611.001]
  • (PMID = 20182716.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2895900
  • [Investigator] Katai H; Takashima S; Kinoshita T; Yamamura Y; Kunisaki T; Tajiri T; Takenaka A; Otsuji E; Fuji Y; Tsurumaru M; Ogawa K; Saito H; Ota T; Nagai H; Yamazaki Y; Kaminishi M; Takiyama W; Sakuramoto S; Sasaki M; Tanigawa N; Hirakawa K; Fujiya T; Fujii H; Iwasaka N; Ooi E; Matsubara Y; Matsushita T; Tatsumi M; Yamamoto Y; Arita T; Wakabayashi G; Takiguchi N; Kitamura M; Nagata N; Watanabe S; Kimura W; Bandai Y; Kasai S; Hishiyama T; Yamada T; Kitano S; Monden M; Takabatake T; Yoshikawa T; Maehara Y; Oshita H; Nashimoto A; Ishida H; Sasaki I; Ishikawa H; Tani T; Kurita H; Kumagai K; Kusano M; Furukawa H; Konishi F; Kondo Y; Nakada K; Yamamoto M; Iwasaki Y; Inada T; Arai K; Sunagawa M; Shimizu T; Tamiya Y; Tokunaga A; Takayama T; Ishida Y; Ninomiya M; Goto M; Uyama I; Naito H; Mochizuki H; Miyata N; Naito H; Oka M; Tsuji T; Miyashiro I; Aoki T; Kanematsu T; Morita T; Tanaka K; Monden T; Yamasaki Y; Takahashi M; Fujii Y; Shiozaki H; Sugiyama Y
  •  go-up   go-down


56. Abaalkhail F, Castonguay M, Driman DK, Parfitt J, Marotta P: Lobular capillary hemangioma of the liver. Hepatobiliary Pancreat Dis Int; 2009 Jun;8(3):323-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lobular capillary hemangioma (LCH) is a benign vascular tumor that is rare in adults and has never been reported in the liver.
  • METHODS: LCH as a large asymptomatic hepatic mass was seen in a 35-year-old female.
  • RESULTS: A large vascular hepatic lesion was observed in an asymptomatic 35-year-old female.
  • Large vascular hepatic lesions pose significant difficulties in discerning benign from potentially malignant conditions.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Liver Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502177.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 6
  •  go-up   go-down


57. Sidani SM, Tawil AN, Sidani MS: Extraction of a large self-amputated colonic lipoma: A case report. Int J Surg; 2008 Oct;6(5):409-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraction of a large self-amputated colonic lipoma: A case report.
  • Despite being the most common benign tumor of nonepithelial origin in the colon, colonic lipomas are nonetheless considered a rare occurrence.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colonoscopes. Colonoscopy / methods. Lipoma / pathology. Lipoma / surgery
  • [MeSH-minor] Barium Sulfate. Colectomy / methods. Enema / methods. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947813.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


58. Niimi R, Matsumine A, Kusuzaki K, Shintani K, Nakamura T, Kotera H, Murata T, Uchida A: Epithelioid hemangioendothelioma after radiotherapy for congenital hemangioma: a case report. Med Oncol; 2010 Mar;27(1):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 28 years of age, the patient noticed a large tumor mass with intractable pain at the antero-lateral aspect of the proximal lower leg, and she presented to our hospital.
  • Although malignant change in a benign vascular tumor is extremely rare, irradiation can induce malignant transformation of a hemangioma.


59. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • These tumors constitute a difficult clinical problem to handle.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • In meningothelial meningioma the same comparison yielded six significantly differentially expressed peaks (P < 0.001), which to a large degree separated the invasive from noninvasive tissue (area under ROC curve = 0.873).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2113-20 [17428078.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):343-5 [17471020.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):325-31 [15264244.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2319-24 [15330178.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):905-12 [17977259.001]
  • [Cites] Acta Neurol Scand. 1993 Mar;87(3):243-7 [8475698.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 [16515582.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Surg Neurol. 1997 Nov;48(5):501-6 [9352816.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1853-63 [16736004.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):461-6 [6310067.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:44-8 [11386825.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):247-53 [16229881.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2103-6 [16990423.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(1):45-51 [15860936.001]
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


61. Chiesa AG, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A: Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol; 2010 Mar;29(2):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
  • At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed.
  • Optimal sampling and adequate sampling were defined as at least 1 section per centimeter of maximum tumor dimension and at least 1 section per 2 cm of maximum tumor dimension, respectively.
  • Tumor size ranged from 8 to 39 cm (mean 20 cm).
  • The sampling of the ovarian tumor was optimal in 28 cases and adequate in 5 cases.
  • The tumor was incompletely removed and recurred in the pelvis 1 year later.
  • Ten months later, the tumor re-recurred in the pelvis and could only be drained because of the patient's advanced age and her poor medical status.
  • The second patient with recurrent tumor had undergone a cystectomy and full staging for a borderline OInMT.
  • However, borderline OInMTs are usually large and heterogeneous, and the standard sampling protocol for them is not evidence based.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Histocytochemistry. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Terminology as Topic. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Nov;29(6):552-3; author reply 553-4 [20881857.001]
  • (PMID = 20173495.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Styczynski J, Lasek W, Wysocki M: Calcified fibromatosis of the neck in 4-year old girl: rapid growth, rapid therapy. Int J Pediatr Otorhinolaryngol; 2005 Jun;69(6):847-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An unusual case of 4-year old girl presenting large tumor of the neck with massive calcification is described.
  • The growth of the tumor was rapid and mediastinal involvement was observed.
  • The final diagnosis showed benign nature of tumor with microscopic features of fibromatosis calcificans.
  • After surgical resection of neck tumor, residual mass persisted both in the neck and in the mediastinum in 6 years of follow-up without signs of progression.
  • [MeSH-major] Calcinosis / diagnosis. Calcinosis / surgery. Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / surgery. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / surgery

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885340.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


63. Zafrakas M, Chorovicer M, Klaman I, Kristiansen G, Wild PJ, Heindrichs U, Knüchel R, Dahl E: Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. Int J Cancer; 2006 Mar 15;118(6):1453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GABRP downregulation in breast cancer was confirmed by quantitative RT-PCR in cryopreserved breast tumour and normal breast tissue specimens (n = 22), in archival formalin-fixed, paraffin-embedded tissue specimens (n = 32), as well as in breast cancer cell lines (n = 8).
  • Furthermore, a significant downregulation of GABRP was noted in large (pT3-pT4) (p = 0.044) primary breast tumours.
  • Non-radioisotopic ISH showed strong GABRP expression in normal epithelial and benign papilloma breast cells, but no signal could be detected in invasive ductal carcinoma.
  • Altogether, these data suggest that GABRP is progressively down-regulated with tumour-progression, and that it may be useful as a prognostic marker in breast cancer.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / genetics. Protein Subunits / genetics. Receptors, GABA-A / genetics
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization / methods. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction


64. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJ, Adema GJ: Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol; 2009 Aug;11(4):394-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.
  • The brain is a specialized immune site representing a unique tumor microenvironment.
  • The availability of fresh brain tumor material for ex vivo analysis is often limited because large parts of many brain tumors are resected using ultrasonic aspiration.
  • We analyzed ultrasonic tumor aspirates as a biosource to study immune suppressive mechanisms in 83 human brain tumors.
  • Lymphocyte infiltrates in brain tumor tissues and ultrasonic aspirates were comparable with respect to lymphocyte content and viability.
  • Applying ultrasonic aspirates, we detected massive infiltration of CD4+FoxP3+CD25(high) CD127(low) regulatory T cells (Tregs) in glioblastomas (n = 29) and metastatic brain tumors (n = 20).
  • No Treg accumulation was observed in benign tumors such as meningiomas (n = 10) and pituitary adenomas (n = 5).
  • A significant Treg increase in blood was seen only in patients with metastatic brain tumors.
  • Tregs in high-grade tumors exhibited an activated phenotype as indicated by decreased proliferation and elevated CTLA-4 and FoxP3 expression relative to blood Tregs.
  • Functional analysis showed that the tumor-derived Tregs efficiently suppressed cytokine secretion and proliferation of autologous intratumoral lymphocytes.
  • Most tumor-infiltrating Tregs were localized in close proximity to effector T cells, as visualized by immunohistochemistry.
  • Furthermore, 61% of the malignant brain tumors expressed programmed death ligand-1 (PD-L1), while the inhibitory PD-1 receptor was expressed on CD4+ effector cells present in 26% of tumors.
  • In conclusion, using ultrasonic tumor aspirates as a biosource we identified Tregs and the PD-L1/PD-1 pathway as immune suppressive mechanisms in malignant but not benign human brain tumors.
  • [MeSH-major] Antigens, CD / metabolism. Apoptosis Regulatory Proteins / metabolism. Brain Neoplasms / immunology. Immunosuppression. T-Lymphocytes, Regulatory / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2007 Jan;28(1):12-8 [17129764.001]
  • [Cites] Trends Immunol. 2006 Aug;27(8):387-93 [16814607.001]
  • [Cites] Cancer Immunol Immunother. 2007 Mar;56(3):271-85 [16819631.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):371-80 [17210720.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):771-5 [17220874.001]
  • [Cites] Trends Mol Med. 2007 Mar;13(3):108-16 [17257897.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):18-29 [17185041.001]
  • [Cites] Immunol Rev. 2006 Aug;212:131-48 [16903911.001]
  • [Cites] Springer Semin Immunopathol. 2006 Aug;28(1):17-23 [16838179.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):430-7 [16961139.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6983-90 [17082613.001]
  • [Cites] Trends Immunol. 2006 Dec;27(12):541-4 [17045841.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):95-105 [17315190.001]
  • [Cites] Cancer Immun. 2007;7:12 [17691714.001]
  • [Cites] Cancer Immunol Immunother. 2007 Nov;56(11):1687-700 [17571260.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2023-30 [17682068.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4919-28 [17878392.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7424-30 [18025186.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1794-802 [18076066.001]
  • [Cites] J Transl Med. 2007;5:67 [18093335.001]
  • [Cites] Histopathology. 2002 Jan;40(1):2-11 [11903593.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):249-58 [12874258.001]
  • [Cites] Nat Rev Immunol. 2003 Jul;3(7):569-81 [12876559.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):3-11 [12952281.001]
  • [Cites] Cancer Treat Res. 2004;117:249-62 [15015564.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4572-7 [15070759.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):29-39 [15072445.001]
  • [Cites] Clin Neuropathol. 2004 Mar-Apr;23(2):47-52 [15074577.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Neurosurg Rev. 1984;7(2-3):173-7 [6493516.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):169-78 [7834443.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4882-92 [10202033.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Neurosurgery. 1999 Oct;45(4):893-5 [10515485.001]
  • [Cites] Cancer Immunol Immunother. 2005 Apr;54(4):307-14 [15599732.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):328-41 [15716863.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1061-7 [15809351.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] J Clin Invest. 2006 Feb;116(2):485-94 [16424940.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3294-302 [16540683.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):234-43 [16723631.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1701-11 [16818678.001]
  • [Cites] Eur J Immunol. 2007 Jan;37(1):129-38 [17154262.001]
  • (PMID = 19028999.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Apoptosis Regulatory Proteins; 0 / CD274 protein, human; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  • [Other-IDs] NLM/ PMC2743219
  •  go-up   go-down


65. Vered M, Dobriyan A, Buchner A: Congenital granular cell epulis presents an immunohistochemical profile that distinguishes it from the granular cell tumor of the adult. Virchows Arch; 2009 Mar;454(3):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital granular cell epulis presents an immunohistochemical profile that distinguishes it from the granular cell tumor of the adult.
  • Congenital granular cell epulis (CGCE), a rare benign lesion arising from the mucosa of the alveolar ridges of the jaws in newborns, has a clinical course characterized by lack of further growth after birth.
  • Histomorphologically, it resembles a granular cell tumor (GCT) of the adult.
  • We submitted a series of five CGCEs to a large panel of antibodies in order to trace the origin of the constituent granular cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gingival Neoplasms / congenital. Gingival Neoplasms / metabolism. Granular Cell Tumor / congenital. Granular Cell Tumor / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child. 1989 Jan;64(1):145-7 [2923466.001]
  • [Cites] J Indian Soc Pedod Prev Dent. 2004 Jun;22(2):63-7 [15491088.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):291-8 [15791574.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):150-9 [19192059.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10 ):963-9 [14559978.001]
  • [Cites] Pediatrics. 2001 Feb;107(2):E22 [11158496.001]
  • [Cites] Ann Plast Surg. 1994 Sep;33(3):320-1 [7985971.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jul;104(1):e45-8 [17577543.001]
  • [Cites] Br J Oral Surg. 1980 Dec;18(3):238-43 [